Inhalers with airway disks having discrete airway channels and related disks and methods
Abstract
The dry powder inhaler has an isolated, typically identified airway passage that extends radially. These airway passages are adapted to sequentially form part of the inhalation pathway for delivering dry powder within the inhaler.
Term
Projected expiry 25 September 2029.
- Priority
- Filed
- Published
- Today
- Projected expiry
25 claims: 11 independent, 14 dependent
- 1ドライパウダードーズ容器アセンブリであって、 相背向する上下主面および周方向に離隔された複数のドーズ容器を有するドーズ容器ディスクと、 前記ドーズ容器ディスクの上または下に位置し、周方向に離隔された複数の気道通路を備えた第1の気道ディスクと、を備えたドライパウダードーズ容器アセンブリ。
- 2前記ドーズ容器内のドライパウダーと、第2の気道ディスクとをさらに備え、前記第2の気道ディスクは、前記ドーズ容器ディスクを挟んで前記第1の気道ディスクと整列され、かつ、周方向に離隔された複数の気道通路を備えており、 前記第1の気道ディスクの前記通路の少なくとも1つは、前記第2の気道ディスクの前記通路の対応する少なくとも1つと、協働作用する通路を画成すべく、前記ドーズ容器の少なくとも1つを介して整列されていることを特徴とする請求項1に記載のドライパウダードーズ容器アセンブリ。
- 3前記第1の気道ディスクは、前記ドーズ容器ディスクの上側または下側主面および/またはその上のシーリング材に当接しており、前記第2の気道ディスクは、前記上側または下側主面の他方またはその上のシーリング材に当接していることを特徴とする請求項2に記載のドライパウダードーズ容器アセンブリ。
- 4前記気道通路は、前記気道ディスクを横切って半径方向に細長く延在しており、前記細長通路は、互いに反対側にある第1の端部分および第2の端部分を有しており、前記第1の端部分は実質的に開放され、前記第2の端部分は実質的に閉鎖されており、前記第1の端部分は、前記ドーズ容器ディスクの内周または外周の近くに位置しており、前記第2の端部分は、それぞれのドーズ容器の上または下に位置していることを特徴とする請求項1~3の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 5前記ドーズ容器ディスクは、 周方向に離隔されかつ前記ドーズ容器の少なくとも一部を画成すべく前記ドーズ容器ディスクを貫通して延在する複数のドーズ容器開口と、 前記ドーズ容器開口の上に位置している第1のシーリング材と、 前記ドーズ容器開口の下に位置している第2のシーリング材と、をさらに備えており、 前記第1の気道ディスクは、周方向に離隔された複数の開口を備え、前記複数の開口の少なくとも1つは、各気流通路に関連付けられており、前記第1の気道ディスク開口の各々は、前記第1または第2のシーリング材を介して、それぞれのドーズ容器の上または下に配置されていることを特徴とする請求項1に記載のドライパウダードーズ容器アセンブリ。
- 6前記協働作用する気道ディスク通路は、該気道ディスク通路間に保持された前記少なくとも1つのドーズ容器からドライパウダーを送出するための一回使用気道経路または2回使用気道経路を画成することを特徴とする請求項2~3の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 7前記第1の気道ディスクまたは前記ドーズ容器ディスクは、その内周または外周にギア歯を備え、前記ギア歯は、利用者がそれぞれの気道ディスク通路をマウスピースへの出口流路として用いて前記少なくとも1つのドーズ容器から放出されたドライパウダーを吸入できるように、割出し機構と協働して、前記ドーズ容器アセンブリを連続的に投与位置に回転させ、少なくとも1つの気道ディスク通路を前記マウスピースに連通させるように構成されていることを特徴とする先行する請求項の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 8前記第1の気道ディスクは、前記第1の気道ディスク通路の下に閉鎖面の床を有し、前記第1の気道ディスク通路は、各々、上方に延びる一対の側壁を備えており、前記第2の気道ディスクは、周方向に離隔された開口を伴う天井を有し、前記開口の少なくとも1つは、各ドーズ容器開口の上に第1のシーリング層を介して配置され、前記第2の気道ディスク通路は、各々、前記第1の気道ディスク通路の前記側壁に対向して下方に延びる一対の側壁を備えていることを特徴とする請求項2~3,4,6~7の何れか一項に記載にドライパウダードーズ容器アセンブリ。
- 9前記ドーズ容器ディスクは、第1の半径において周方向に離隔された複数の開口の第1の列と、第2の半径において周方向に離隔された複数の開口の第2の列とを備え、前記第1の列および前記第2の列は、前記ディスクの中心と同心に配列され、ドーズ容器開口の前記第1の列は、ドーズ容器開口の前記第2の列の半径方向に延びる中心線から周方向にずれて半径方向に延びる中心線を有しており、前記第1の気道ディスク通路は、交互に配置された異なる半径方向長さの通路を備え、前記長さの一方は、前記気道ディスクの内周または外周から前記第1の列におけるドーズ容器まで延びる通路に対応し、前記長さの他方は、前記気道ディスクの内周または外周から前記第2の列のドーズ容器開口まで延びる通路に対応することを特徴とする請求項1~8の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 10前記第1の気道ディスクは、複数の短い気道通路および複数の長い気道通路を備え、前記短い気道通路は、前記ドーズ容器開口の前記第1の列に関連付けられ、前記長い気道通路は、前記ドーズ容器の前記第2の列に関連付けられており、前記短い気道通路および前記長い気道通路は、前記第1の気道ディスクの周方向に交互に隣接して配置されていることを特徴とする請求項1~9の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 11前記第1の気道ディスク通路は、それぞれのドーズ容器の上方に第1の距離で延びてから向きを変え、前記ドーズディスクの内周または外周に向かって第2の距離で延び、さらに、下方に第3の距離で延びる部分を有するように構成され、前記第3の距離は、少なくとも前記第1の距離と同じであることによって、前記吸入器からのドライパウダーの望ましくない漏出を阻止する曲線状の気流経路部分が形成されていることを特徴とする請求項1~10の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 12前記第1の気道ディスク通路は、開口端を有しており、前記開口端は、いずれも、前記第1の気道ディスクの内周または外周に位置していることを特徴とする請求項1~11の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 13前記ドーズ容器ディスクおよび前記第1および第2の気道ディスクは、円形の内周を有すると共に実質的に同一の直径を有しており、前記ドーズ容器ディスクは、その内周に凹部を有し、前記第1の気道ディスクは、その内周に、周方向に離間されかつ下方に延びる複数のタブを備え、前記第2の気道ディスクは、その内周に、周方向に離間されかつ上方に延びる複数のタブを備え、前記タブの1つは半径方向の延出部分を有し、前記延出部分は、前記ドーズ容器ディスクの前記凹部に係合し、前記ドーズ容器ディスクを前記第1および第2の気道ディスクに対して位置決めするようになっており、前記下側または上側気道ディスクの少なくとも1つは、潰しリブを備えており、前記上側および下側気道ディスクは、前記ドーズ容器ディスクをそれらの間に緊密に挟んで、互いに圧入され、これによってしっかりと取り付けられた一体のアセンブリを形成するようになっていることを特徴とする請求項2~3、6~8の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 14前記第1の気道ディスクの内周壁または外周壁に空気抜き孔をさらに備え、前記空気抜き孔は、前記第1の気道ディスクのそれぞれの気道通路と1つになるそれぞれの空気経路に連通しており、各空気抜き孔および関連する空気経路は、対応する気道ディスク通路ごとに設けられていることを特徴とする先行する請求項の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 15前記協働作用する通路は、気道ディスク通路の協働作用する対であり、前記協働作用する対は、それらの間に保持された対応ドーズ容器の投与中に流体連通し、前記対応ドーズ容器と共に略U字状の気流経路を画成するように構成され、前記U字形状の長辺は、前記ディスクの少なくとも一部を横切って半径方向に延在するように配向された各通路に対応していることを特徴とする請求項2~3、6~8,13,14の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 16前記周方向に離隔された気道通路は、半径方向に延在しており、前記第1の気道ディスクの各気道通路は、対応するドライパウダー出口を画成しており、前記ドライパウダー出口開口は、周方向に離間しており、前記第1の気道ディスクの外周に位置していることを特徴とする先行する請求項の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 17吸入器と組み合わされており、前記吸入器は、吸入口を有する吸入器本体を備え、前記ドーズ容器ディスクおよび/または前記第1の気道ディスクは、所定方向に移動すべく付勢され、前記吸入器本体内の出口気流経路に関連付けられた界面または壁に密封係合するように構成されていることを特徴とする請求項1~16の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 18吸入器と組み合わされており、前記吸入器は、吸入口を有する吸入器本体を備え、前記吸入器は、前記第1の気道ディスクの内周または外周と前記吸入器内の出口気流経路に関連付けられた壁との間に位置する少なくとも1つのシールを備えていることを特徴とする請求項1~16の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 19前記吸入器は、前記ドーズ容器ディスクの外周または内周の近くに位置した負荷ポストと連動するレバーを備え、前記レバーの運動によって、前記負荷ポストが、前記ドーズ容器ディスクアセンブリをマウスピースまたは前記マウスピースと流体連通している出口気流経路部材のいずれかに押すようになっていることを特徴とする請求項17に記載のドライパウダードーズ容器アセンブリ。
- 20突刺機構を有する吸入器と組み合わされており、前記突刺機構は、(a)回転せずに垂直方向の直線移動によって、前記シーリング材を突き刺すように構成されたコルク・スクリュー突刺具、(b)前記シーリング材を突き刺すように構成された溝付き突刺具であって、前記溝付き突刺具は、3つまたは4つのローブを備えており、前記第1の気道ディスクは、周方向に離隔された開口を備える平坦面を有しており、前記開口は、前記溝付き突刺具の前記3つまたは4つのローブに対応する3つまたは4つのローブを備える周辺形状を有する、溝付き突刺具、(c)中実突刺具、の少なくとも1つを備えていることを特徴とする請求項1~16の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 21前記ドーズ容器アセンブリは、薬学的活性剤を有するドライパウダーを含んでおり、前記活性剤は、以下の気管支拡張剤:アルブテロール、サルメテロール、エフェドリン、アドレナリン、フェノテロール、フォルモテロール、イソプレナリン、メタプロテレノール、フェニレフリン、フェニルプロパノールアミン、ピルブテロール、レプロテロール、リミテロール、テルブタリン、イソエタリン、ツロブテロール、または(-)-4-アミノ-3,5-ジクロロ-α―[[[6-(2-(2-ピリニジニル)エトキシ]ヘキシル]メチル]ベンゼンメタノールの一種または複数種を含んでおり、 前記気管支拡張剤は、塩、エステル、または溶媒和物の形態で用いて、これによって、前記薬剤の活性および/または安定性が最適化するようになっていてもよいことを特徴とする先行する請求項の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 22前記協働作用する通路は、協働作用する気道通路の対であり、前記気道通路の対は、それらの間に保持された対応ドーズ容器を介して半径方向に延在し気流経路を画成しており、前記気流経路は、前記ドーズ容器から出た気流が、該気流内に混入されているドライパウダーと共に、1回以上の90度方向変換部を通過することによって、凝集を阻止するように構成されていることを特徴とする請求項2~4のいずれかの前記ドーズ容器アセンブリを保持するように構成されたドライパウダー吸入器。
- 23前記ドーズ容器ディスクは、組合せ薬剤の送達を可能とするために、互いに異なるドライパウダーを保持する2つ以上の積層されたドーズディスクとして設けられていることを特徴とする先行する請求項の何れか一項に記載のドライパウダードーズ容器アセンブリ。
- 24ドーズ容器アセンブリを製造する方法であって、 周方向に離隔された複数の開口を備える上側および下側主面を有するドーズ容器ディスクを準備するステップと、 シーリング層を前記ドーズ容器ディスクの前記上側または下側主面の一方に取り付けるステップと、 前記ドーズ容器ディスク開口にドライパウダーを充填するステップと、 ドーズ容器を密封するために、シーリング層を前記ドーズ容器の他の主面に取り付けるステップと、 少なくとも1つの気道ディスクを準備するステップと、 前記ドーズ容器を、前記少なくとも1つの気道ディスクの周方向に互いに離隔された気道通路に対して、各ドーズ容器が前記少なくとも1つの気道ディスクの前記気道通路の1つと連通するように整列するステップと、 前記少なくとも1つの気道ディスクを前記ドーズ容器ディスクに組み合わせるステップと、を含む、方法。
- 25少なくとも1つの気道ディスクを準備する前記ステップは、2つの気道ディスク、具体的には、上側および下側気道ディスクを準備することによって行われ、 前記整列するステップは、前記ドーズ容器を前記上側および下側気道ディスクの両方の周方向において互いに離隔された気道通路に対して、各ドーズ容器が前記上側および下側ディスクの両方の前記気道通路の1つと連通するように整列することによって行われ、 前記組み合わせるステップは、前記ドーズ容器ディスクを挟んで、前記上側および下側気道ディスクを互いに圧入することによって行われる、請求項24に記載の方法。
Independent claims25
144 paragraphs, as filed
[Cross-reference of related applications] This application claims the gains and priorities of US Provisional Application No. 61 / 100,482 filed September 26, 2008 and US Provisional Application No. 61 / 148,520 filed January 30, 2009. And the disclosures are hereby incorporated by reference in the same way that they are described in their entirety.
[Field of invention] The present invention relates to an inhaler and is particularly suitable for a dry powder inhaler.
In general, well-known single-dose / multi-dose dry powder inhalers (DPI) are already accepted alternatives to pressurized metered dose inhalers (pMDI). DPI may use (a) individual pre-weighed doses (dose) in the blister containing the drug that can be inserted into the device prior to administration, or (b) the appropriate dose. A bulk powder container can be used that is configured to administer a continuous dose of the drug to the patient through a dosing chamber that is designed to administer. Please refer to Non-Patent Documents 1 and 2 in general.
In terms of operation, the DPI device aims to administer a uniform aerosol dispersion of dry powder with the desired physical form (eg particle size) into the patient's respiratory tract and direct it to the desired internal retention site. ..
However, unfortunately, some dry powder inhalers may have some amount of drug left in the device, and this remaining drug may be delivered with other drug doses. This tends to occur especially when the user has activated the inhaler but has not inhaled the indexed drug dose.
<p><nplcit num="1"><text>Prime et al., Review of Dry Powder Inhalers, 26 Adv. Drug Delivery Rev., pp. 51-58 (1997)</text></nplcit><nplcit num="2"><text>Hickey et al., A new millennium for inhaler technology, 21 Pharm. Tec., N. 6, pp. 116-125 (1997)</text></nplcit></p>
<p> There is still a need for alternative inhalers and / or dose containment devices that can be used to deliver the drug.</p>
<p> Embodiments of the present invention line up straight with the inhalation port and form part of the inhalation route to the inhalation port for taking in dry powder from each dose container and administering the dry powder to the inhaler user. An individual airway passage is provided for a dose container assembly that can be defined for one or more dose containers.</p><p> Some embodiments include (a) a dough container disc having a plurality of dough containers separated from each other in the upper and lower main surfaces facing each other and in the circumferential direction, and (b) located above or below the dough container disk. It is aimed at a dry powder dose container assembly that features at least one airway disc. At least one airway disc comprises multiple airway passages separated in the circumferential direction. The dough container can have a dry powder sealed in the doze container.</p><p> Embodiments of the present invention are directed to dry powder dose container assemblies. This assembly is (a) a doze container disc with multiple dough containers separated in the circumferential direction, with the dough container in the dough container (typically a predetermined amount or a measured amount). It comprises a doze container disc with dry powder, (b) an upper airway disc located above the doze container disc, and (c) a lower airway disc located below the doze container disc. There is. The upper and lower airway discs each have a plurality of passages separated in the circumferential direction, and a pair of lower airway disc passages and upper airway disc passages has at least one corresponding dose container between them. They are placed side by side in a straight line with each other.</p><p> The dose container may be used in combination with an inhaler. The inhaler may include an inhaler body having an inhalation port and a puncture mechanism. During operation, the dose vessel is indexed to the suction position and the puncture mechanism moves through the airway disc opening, piercing and entering the first and second sealing layers, and then closing the airway disc opening, while It is configured to remain in or retract from the dose disc opening, thereby allowing dry powder falling from the dose disc to be taken into the airway passage.</p><p> In some embodiments, the dose vessel assembly comprises both upper and lower airway discs. Each of these airway discs has a plurality of short airway passages and a plurality of long airway passages. The short airway passage is associated with the first row of dose vessel openings, and the long airway passage is associated with the second row of dose vessel openings. Short airway passages and long airway passages are arranged so as to alternate around the disc adjacent to each other in the circumferential direction.</p><p> In some embodiments, the pair of upper and lower airway disc passages work together (eg, by providing a sink trap structure) to prevent unwanted leakage of dry powder from the inhaler. Demarcates the airflow passage.</p><p> Other embodiments are directed to dry powder inhalers. The inhaler includes an inhaler body having an inhaler port, a dose container assembly held in the inhaler body, a dose container opening mechanism configured to open the dose container at the administration position in the inhaler, and a dose container. It comprises an indexing mechanism, which is configured to rotate the assembly to the dosing position.</p><p> The dose vessel assembly comprises a dose vessel disc having a plurality of circumferentially spaced openings, the openings containing dry powder. The dose vessel assembly also comprises a lower airway disc with multiple airway passages (with side walls extending upwards) located beneath the dose vessel disc. Each of the lower airway passages communicates with at least one dose vessel opening, which allows the lower airway disc passages to communicate sequentially with the inhalation port to prevent inadvertent overdose. Multiple single-use or multi-use inhalation delivery routes isolated from each other will be defined.</p><p> The dose vessel assembly is (a) a dose vessel disc having a plurality of openings separated in the upper and lower main surfaces facing each other and in the circumferential direction, and the first and second sealants are the dough vessel discs. Attached to the upper and lower main surfaces, each floor and ceiling of the dough container opening is defined, thereby forming a dough container for holding the dry powder, with the doze container disc and (b. The upper airway disc, which is located above the dose container disc and has multiple circumferentially separated passages (with side walls extending downward), and ( c) With a lower airway disc located beneath the doze vessel, with multiple circumferentially separated passages (with side walls extending upward). , Is equipped. A pair of lower airway disc passages and upper airway disc passages are arranged in a straight line with at least one corresponding dose container sandwiched between them.</p><p> Yet another embodiment is directed to a method of operating an inhaler. This method is (a) a step of providing a dose vessel ring with staggered concentric openings, the openings being sealed by upper and lower sealing layers located above and below, respectively. It defines a sealed dose container, the dose container ring is attached to an airway passage disc with multiple airway passages separated in the circumferential direction, and at least one of the airway passages corresponds to each dose container. Steps, (b) rotate the dose vessel ring and disc together to bring each dose vessel and corresponding airway passage to the dosing position in the inhaler, and (c) puncture mechanism. Steps to move forward, open both sealants and release dry powder from the dose vessel into the corresponding airway passages, and (d) leave the puncture mechanism in a protruding position or at least partially retract the puncture mechanism. And (e) the step of completely retracting the puncture mechanism from the airway disc opening after the residual step described above, and (f) the passage being reused only once or used for any subsequent inhalation delivery. Includes a step to isolate the airway passage associated with the already released dry powder from the inhalation flow path, in order to prevent it.</p><p> An additional embodiment is directed to a method of manufacturing a dose container assembly. This method involves (a) providing a dosing vessel disc with upper and lower main surfaces with multiple openings separated in the circumferential direction, and (b) providing a sealing layer on the upper or lower main surface of the dosing vessel disc. One of the steps to attach to one of the, (c) the step of filling the dough container disc opening with dry powder, and (d) the step of attaching the sealing layer to the other main surface of the doze container to provide a sealed doze container. And (e) the step of placing the dose vessel disc between the upper and lower airway discs, and (f) for the airway passages isolated from each other in the circumferential direction on the upper and lower airway discs, respectively. Steps to place the dose container in a straight line so that it communicates with one of the airway passages of both the upper and lower airway discs, and (g) sandwich the upper and lower airway discs between them. Includes mounting steps and.</p><p> In some embodiments, the dose vessel assembly allows operation independent of orientation, even if the inhaler is held face up or face side down. Also, the dose is taken from each doze container, and as a result, the dry powder is retained in each airway pathway, which makes it difficult to overdose the inhaler. Can be done. In some embodiments, the inhaler may also be provided with an overdose protection feature that blocks the administration of accumulated doses released from different dose containers.</p><p> It should be noted that the aspects of the invention described for one embodiment may be included in another embodiment, even though they are not specifically described in this regard. That is, the features of all embodiments and / or any embodiment may be combined in any way and / or in any coordination. The applicant initially has the right to modify any claims originally filed, or to file any new claims accordingly, eg, any claims originally filed as such. It reserves the right to be subordinate to and / or amended to include any feature of any other claim, even if not stated. These and other aspects and / or aspects of the invention will be further clarified by the detailed description described below.</p>
<figref num="1A">FIG. 3 is a front perspective view of a covered inhaler according to some embodiments of the present invention.</figref><figref num="1B">It is a front perspective view of the inhaler shown in FIG. 1A with the cover in the open position according to some embodiments of the present invention.</figref><figref num="2A">FIG. 6 is an upward perspective view of an exemplary dose container assembly according to some embodiments of the present invention.</figref><figref num="2B">It is an exploded view of the assembly shown in FIG. 2A.</figref><figref num="2C">FIG. 3 is a partial cut-out view of an airway passage lined up with two dose containers according to some embodiments of the present invention.</figref><figref num="2D">FIG. 3 is an upper perspective view of another exemplary dose container assembly according to some embodiments of the present invention.</figref><figref num="2E">It is an exploded view of the dose container assembly shown in FIG. 2D according to the embodiment of the present invention.</figref><figref num="2F">It is an exploded view of the doze container assembly which has a laminated doze disk by embodiment of this invention.</figref><figref num="2G">FIG. 3 is a partial cut-out view of an airway passage arranged in a straight line with two concentric rows of staggered dose vessels according to some embodiments of the present invention.</figref><figref num="3A">FIG. 3 is an upward perspective view of a dose container ring according to some embodiments of the present invention.</figref><figref num="3B">FIG. 3 is an upward perspective view of a dose vessel ring according to some other embodiment of the present invention.</figref><figref num="3C">FIG. 6 is a partial cut-out view of a single dose container according to some embodiments of the present invention.</figref><figref num="3D">FIG. 6 is a partial cut-out view of a single dose container according to some embodiments of the present invention.</figref><figref num="4A">It is an enlarged upper perspective view of the lower airway disc according to some embodiments of the present invention.</figref><figref num="4B">It is a top view of the lower airway disc according to some embodiments of the present invention.</figref><figref num="4C">It is a bottom view of an exemplary lower airway disc.</figref><figref num="5A">It is an enlarged upper perspective view of the upper airway disc according to some embodiments of this invention.</figref><figref num="5B">FIG. 5 is an enlarged perspective view of an upper airway disc according to another embodiment of the present invention.</figref><figref num="6">FIG. 5 is an enlarged partial view of the dose container assembly shown in FIG. 2A according to an embodiment of the present invention.</figref><figref num="7A-7C">FIG. 5 is a partial cut-out view of a dose vessel assembly in an inhaler that works in concert with a puncture mechanism in a three-step operating procedure according to some embodiments of the present invention.</figref><figref num="8A">Inhalation with a doze container assembly configured to be aligned with an airway passage in a disc having a "sink trap" that prevents leakage of the outer ring of the doze container according to some embodiments of the present invention. It is a lower perspective view which shows by cutting a part of a container.</figref><figref num="8B">8A, showing that according to some embodiments of the present invention, they are arranged in line with the airway passages in the disc that define a "sink trap" that prevents leakage of the inner ring of the dose vessel. It is a side perspective view of the apparatus shown in.</figref><figref num="9A">FIG. 3 is an upward perspective view of a dose container assembly and a puncture mechanism according to some embodiments of the present invention.</figref><figref num="9B">It is a top view of the apparatus shown in FIG. 9A.</figref><figref num="9C">It is a side view of the apparatus shown in FIG. 9A.</figref><figref num="10">It is a partial decomposition view of the apparatus shown in FIG. 9A according to some embodiments of the present invention.</figref><figref num="11">It is an assembly top view of a part of the apparatus shown in FIG.</figref><figref num="12">It is a side sectional view along line 12-12 of FIG. 11 showing the operation of the outer ring according to some embodiments of the present invention.</figref><figref num="13">It is an assembly top view of a part of the apparatus shown in FIG.</figref><figref num="14">It is a side sectional view along the line 14-14 of FIG. 13 which shows the operation of the inner ring by embodiment of this invention.</figref><figref num="15A">It is a top view of the dose container ring according to some embodiments of this invention.</figref><figref num="15B">It is a partially enlarged view of a part of the ring shown in FIG. 15A.</figref><figref num="16">It is a side view of the ring shown in FIG. 15A.</figref><figref num="17A">FIG. 3 is an enlarged partial cut-out view of an inhaler with separate airway passages and long airway passages for each dose container according to some embodiments of the present invention.</figref><figref num="17B-17D">FIG. 5 is an enlarged side perspective view in which a part of an inhaler having an urging mechanism according to an embodiment of the present invention is cut off.</figref><figref num="17E">Enlarged cut view of the airflow path and stable airpath junction in the inhaler provided by an urging mechanism as shown, for example, in FIGS. 17B-17D or 17F, 17G, according to an embodiment of the present invention. Is.</figref><figref num="17F">FIG. 5 is a cut-away view of a portion of an inhaler having an alternative urging mechanism (shown inverted from the normal orientation) according to an embodiment of the present invention.</figref><figref num="17G">It is an additional perspective view of the urging mechanism shown in FIG. 17F.</figref><figref num="18A">FIG. 5 is an enlarged partial cut-out view of an inhaler having separate airway passages and short airway passages according to some embodiments of the present invention.</figref><figref num="18B">FIG. 6 is an enlarged partial cut-out view of the inhaler shown in FIG. 18A, showing the indexing mechanism according to some embodiments of the present invention.</figref><figref num="18C">FIG. 5 is an enlarged partial cut-out view of an inhaler having separate airway passages and short airway passages according to some embodiments of the present invention.</figref><figref num="18D">FIG. 6 is an enlarged partial cut-out view of the inhaler shown in FIG. 18C, showing the indexing mechanism according to some embodiments of the present invention.</figref><figref num="18E">It is an exploded side perspective view of the component of the indexing mechanism shown in FIGS. 18C and 18D.</figref><figref num="18F">FIG. 8 is an enlarged side perspective view of some of the assembled components of the suction device shown in FIG. 18E.</figref><figref num="19A">FIG. 6 is an enlarged partial cross-sectional view of an alternative piercing mechanism for a dose container according to some embodiments of the present invention.</figref><figref num="19B">FIG. 6 is an enlarged partial cross-sectional view of a puncture mechanism similar to that shown in FIG. 19A according to some embodiments of the present invention.</figref><figref num="19C">It is a schematic front view of a piercing mechanism having a grooved piercing tool according to some embodiments of the present invention.</figref><figref num="19D">It is an end view of the apparatus shown in FIG. 19C.</figref><figref num="19E">FIG. 5 is a schematic front view of another grooved piercing tool structure according to some embodiments of the present invention.</figref><figref num="19F">FIG. 3 is an end view of a grooved piercing tool having four lobes exemplary according to some embodiments of the present invention.</figref><figref num="19G">It is a substantially partial cut-out view of the inhaler having a puncture structure according to some embodiments of the present invention.</figref><figref num="20">FIG. 5 is an enlarged partial cross-sectional view of an inhaler having a substantially U shaped suction flow path according to some embodiments of the present invention.</figref><figref num="21">FIG. 6 is a flow chart of an exemplary operating process used to operate an inhaler according to some embodiments of the present invention.</figref><figref num="22">FIG. 6 is a flow chart of the process used to manufacture or assemble a dose container assembly according to some embodiments of the present invention.</figref>
Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings showing embodiments of the present invention. However, the present invention may be implemented in many different embodiments and should not be construed as limited to the embodiments described herein. Throughout, similar numbers shall refer to similar elements. In the drawings, some layers, components, or features may be exaggerated for clarity, and dashed lines indicate optional features or operating processes, unless otherwise specified. ing. In addition, the sequence of operations (or processes) is not limited to the order described in the drawings and / or claims, unless otherwise specified. In the drawings, the thickness of lines, layers, features, components, and / or areas may be exaggerated for clarity, and dashed lines are optional features, unless otherwise specified. Or it shows the operation process. Features described with respect to one drawing or embodiment may be associated with other embodiments or drawings without being specifically described or illustrated.
When a feature, such as a layer, region, or substrate, is said to be "on" the other feature or element, the feature is of the other feature or element. It should be understood that it may be located directly on top of it, or that intervening features and / or elements may be present. In contrast, when an element is said to be "directly on" to another feature or element, there are no intervening elements. When one feature or element is referred to as "connected," "attached," or "coupled" to another feature or element. It should also be understood that the feature or element may be directly connected, attached or connected to another element, or may have intervening elements. In contrast, one feature or element is "directly connected", "directly attached", or "directly attached" to another element. When referred to as "coupled)", there are no intervening elements. Even if it is described or illustrated with respect to one embodiment, the features described or illustrated as such may be applied to other embodiments.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the invention. The singular forms "a," "an," and "the" as used herein are also intended to include the plural, unless the context clearly indicates otherwise. The terms "comprises" and / or "comprising" as used herein of the features, strokes, operations, elements, and / or components described. It will identify its existence, but it should be further understood that it does not preclude the existence or addition of one or more other features, processes, operations, elements, components, and / or groups thereof. As used in the present invention, the term "and / or" includes any combination and all combinations of one or more of the items listed in association with each other.
"Under", "below", "lower", "over", "upper", etc. Space-related terminology is used herein to facilitate description of the relationship between one element or feature shown in a drawing and one or more other elements or features. May be used in writing. It should be understood that these terms related to space are also intended to include different orientations of the device during use or operation, in addition to the orientations depicted in the drawings. For example, if the device in the drawing is inverted, an element that is described as being located "under" or "beneath" of another element or feature is another element or feature. It will be oriented "over" of the part. Therefore, the exemplary term "under" includes both upward and downward orientations. The device may be otherwise oriented (ie, rotated 90 ° or in any other direction), in which case the space-related descriptive term used herein. However, it should be interpreted accordingly. Similarly, in the present specification, terms such as "upwardly", "downwardly", "vertical", and "horizontal" are used unless otherwise specified. Used for explanatory purposes only.
Although the terms "first" and "second" are used herein to describe the various areas, layers, and / or areas, these areas, layers, and / or areas. Please understand that should not be limited to these terms. These terms are used only to distinguish one component, area, layer, or area from another component, area, layer, or area. Thus, without departing from the suggestions of the present invention, the first component, area, layer, or area described below may be referred to as the second component, area, layer, or area, and vice versa. Is the same. Throughout, similar part numbers shall refer to similar elements.
Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Have. Terms such as those defined in commonly used dictionaries should be construed to have meaning consistent with their meaning in the context of this specification and related arts and are expressly herein. It should be further understood that unless otherwise specified, it should not be interpreted in an idealized or overly formal sense. Well-known functions or structures may not be described in detail for brevity and / or clarity.
In the description of the present invention described below, some terms are used to refer to the positional relationship between one structure and another. As used herein, "front" or "forward" and its derivatives refer to the general or main direction in which the dry powder travels to be administered to the patient from the dry powder inhaler. pointing. This term is intended to be synonymous with the term "downstream". The term "downstream" is often used in a manufacturing or logistics environment to indicate that a material that is moving or reacting is farther along the process than another material. .. Conversely, "rearward" or "upstream and its derivatives refer in the opposite direction to the forward or downstream direction.
The term "deag glomeration" and its derivatives refer to the inhaler so that the dry powder remains agglomerated or sticky during inhalation or prevents it from agglomerating or sticking. Refers to the fluidization or processing of dry powder in the airway pathway.
The inhalers and methods of the present invention are particularly suitable for retaining a single or multiple doses of a single or multiple doses of a single or multiple granular dry powder material. It should be noted that the dry powder material is formulated for in vivo inhalation dispersion (using an inhaler) to a subject, eg, but not limited to, an animal, typically a human patient. This inhaler has come to be used for inhalation delivery by nasal and / or oral (mouth) breathing, but is typically an oral inhaler.
The terms "sealant", "sealant layer" and / or "sealant material" include forms having at least one layer of at least one type of material, top surface and /. Alternatively, it may be provided as a continuous layer covering the entire underside, or, for example, a strip or strip covering a portion of the device such that it is located above at least one or more target dose container openings. It may be provided as a fragment. The terms "sealing material" and "sealing layer" include single-layer and multi-layer materials, typically including at least one foil layer. The sealing material or sealing layer can be a thin multilayer sealing material having a laminated structure including an elastomer material and a foil material. The sealing layer may be selected to provide drug stability upon contact with the dry powder in each dose container.
The sealed doze container may be configured to block the ingress of oxygen and moisture in order to provide a sufficient shelf life.
The term "primary surface" refers to a surface that has a larger area than other surfaces and can be substantially planar, but may be configured non-planar. For example, the main surface will include protrusions or recesses, for example, when a blister configuration is used. Specifically, the disc can have a top and bottom main surface and a secondary surface (eg, a thick wall) that extends between the two main surfaces and connects them.
Dry powder materials include one or more active pharmaceutical ingredients and biocompatible additives for producing the desired formulation or mixture. As used herein, the term "dry powder" is synonymous with the term "dry powder formulation" and is composed of one or more components within one or more (average) particle size ranges. It means that it can contain substances, auxiliaries, or ingredients. The term "low density" dry powder is about 0.8 g / cm.<sup>3</sup>It means a dry powder having the following densities. In certain embodiments, the low density powder is about 0.5 g / cm.<sup>3</sup>It has the following densities. The dry powder may be a dry powder that tends to be sticky or cohesive.
The term "filling" means supplying a weighed dry powder for bolus or sub-bolus administration. Therefore, each dose container does not necessarily have to be sufficient in volume.
In any case, the individually dispersible amount of the dry powder formulation can contain a single component or multiple components, whether active or inactive. Inactive ingredients include additives added to promote fluidity or to promote aerosolization delivery to the desired subject. The dry powder drug formulation can have a non-uniform active particle size. The device is particularly suitable for dry powder formulations with fine particles in the range of about 0.5 μm-50 μm, typically about 0.5 μm-20.0 μm, and more typically about 0.5 μm-8.0 μm. There is. The dry powder drug formulation may also contain flow-promoting ingredients, typically having a particle size larger than the particle size of the active ingredient. In some embodiments, the flow-promoting component may comprise an excipient having a particle size in the range of about 50 μm to 100 μm. Examples of excipients include lactose and trehalose. Other types of excipients, such as, but not limited to, by the US Food and Drug Administration (FDA), as antifreeze agents (eg, mannitol), as solubility promoters (eg, cyclodextrin), or Sugars approved as other excipients that are "generally recognized as safe (GRAS)" may be used.
The "active agent" or "active ingredient" described herein includes a composition of an ingredient, substance, agent, compound, and substance or mixture that provides a beneficial pharmacological effect. I'm out. Examples of this include foods, dietary supplements, nutrients, drugs, vaccines, vitamins, and other beneficial substances. As used herein, these terms further include any physiologically or pharmacologically active substance that has local and / or systemic effects within the patient's body.
The active ingredient or agent delivered can include antibiotics, antivirals, antiepileptic agents, analgesics, anti-inflammatory agents, and bronchodilators, and may be inorganic and / or organic compounds. Inorganic and / or organic compounds are, but are not limited to, peripheral nerves, adrenergic receptors, choline receptors, skeletal muscle, cardiovascular system, smooth muscle, vasculature, synoptic sites, neuroeffector junctions, It contains drugs that act on the endocrine / hormonal system, immune system, genital system, skeletal system, autologous drug system, digestive and excretory system, histamine system, and central nervous system. Suitable activators are, for example, but not limited to polysaccharides, hormones, hypnotics and sedatives, psychostimulants, tranquilizers, anticonvulsants, muscle relaxants, anti-Parkinsons, analgesics, anti-inflammatory agents. , Muscle contractants, antibacterial agents, anti-malaria agents, hormonal agents including contraceptives, sympathomimetics, polypeptides and / or proteins (which can elicit physiological effects), diuretics, hyperlipidemia Selected from therapeutic agents, anti-androgen agents, anthelmintics, tissue renewal agents, antitumor agents, hypoglycemic agents, nutritional supplements and nutritional supplements, growth supplements, lipids, anti-inflammatory agents, electrolytes, vaccines and diagnostic agents It is good.
The activator may be a natural molecule, may be the result of genetic recombination, or may be a natural or recombinant activator with the addition or removal of one or more amino acids. It may be an analog consisting of. In addition, the activator may contain an attenuated or inactivated virus suitable for use as a vaccine. When the activator is insulin, the term "insulin" refers to naturally extracted human insulin, recombinant human insulin, insulin extracted from bovine and / or porcine and / or other sources, recombinant porcine, bovine. Alternatively, it contains insulin extracted from other suitable donors, and a mixture of any of these. Insulin may be pure (ie, in its substantially purified form), but may also contain commercially formulated excipients. The term "insulin" also includes insulin analogues in which one or more amino acids have been removed or added to natural or recombinant insulin.
Two or more active ingredients or active agents may be included in the aerosolization activator formulation, and the use of the term "agent" or "ingredient" is such that two or more such. It should be understood that the use of aerosols is by no means excluded. In fact, in some embodiments of the invention, it is intended to administer a combination drug that will be mixed in the field.
Examples of diseases, health conditions, or diseases treatable by embodiments of the invention are, but are not limited to, diabetes and other insulin resistant diseases, as well as asthma, COPD (chronic obstructive pulmonary disease). , Viral or bacterial infections, influenza, allergic reactions, cystic fibrosis, and other respiratory illnesses. Dry powder inhalation delivers systemic drugs such as peptides and proteins such as insulin, as well as topical agents such as antibacterial agents, proteolytic enzyme inhibitors, and nucleic acids / origionucleotides. May be used for. For example, antibacterial agents such as anti-tuberculous compounds, proteins such as insulin for diabetes therapy or other insulin resistance related diseases, leuprolide acetate for the treatment of prostate cancer and / or endometriosis. Peptides and nucleic acids or ogligonucleotides for cystic fibrosis gene therapy may be delivered by inhaler. See, for example, Wolff et al .: "Generation of Aerosolation Agents", J. Aerosol. Med.pp. 89-106 (1994). Also, US Patent Application Publication No. 2001/0053761 entitled "ASPB28-Methods for Administering Human Insulin" and US Patent Application Publication No. 2001/0007853 entitled "Methods for Administering Monomer Insulin Similarities". Please refer to the specification. By reference, the contents of these patents shall be included here as if they were completely described.
The typical dose amount of the dry powder mixture, which is the unit dispersed in the inhaler, can be varied depending on the patient's profile, systemic target site, and specific one or more agents. The dose amount and type of drug retained by the dose container system may vary from dose container to dose container or may be the same. In some embodiments, the dose amount of the dry powder can be no more than about 100 mg, typically less than 50 mg, and more typically between about 0.1 mg and about 30 mg.
In some embodiments, for example, in the case of lung disease (ie, asthma or COPD), a total weight of about 5 mmg of dry powder may be supplied (dose amount adjusted to supply this weight). Good). The dose amount of a conventional exemplary dry powder is less than about 50 mg for the average adult, typically between about 10 mg and 30 mg, and typically about 5 mm for the average adolescent patient. Between -10 mg. A typical dose concentration should be between about 1% -5%. Examples of exemplary dry powder agents include, but are not limited to, albuterol, fluticasone, bechrometazone, chromolin, terbutaline, fenoterol, beta stimulants (including long-acting beta stimulants), salmeterol, formoterol, cortical steroids. , And glucocorticoids.
In some embodiments, the amount of bolus or dose administered can be formulated to be higher in concentration than the conventional mixture (so that it contains a higher concentration of active ingredient). In addition, the dry powder formulation can be configured as a lower dose dose as compared to conventional 10-25 mg doses. For example, the amount of each dose of dry powder that can be administered can be less than about 60-70% of the conventional dose. By using the dispersion system provided by some embodiments of the DPI configuration of the present invention, the dose amount for adults is less than about 15 mg, eg, between about 10 μg and 10 mg, and more typically about 50 μg and up. It has been reduced to 10 mg. The concentration of one or more active ingredients is preferably about 5-10%. In other embodiments, the concentration of the active ingredient can be in the range of about 10-20%, in the range of 20-25%, or higher. In certain embodiments, for nasal inhalation, the target dose amount can be from about 12 μg to 100 μg.
In some specific embodiments, during inhalation, the dry powder in a particular drug compartment or blister is a high concentration of one or more active agents that is substantially free of additives (such as excipients). It may be blended as an ingredient. The term as used herein, "substantially free of additives (substantially without additives)" is de Lai powder, substantially pure containing only other non-living pharmaceutical active ingredient a minimum amount It means that it is an active compound. The term "minimum amount" is free of non-active ingredients or very small relative to one or more active ingredients, specifically less than about 10% of the dry powder formulation administered. , Preferably, it is contained in an amount of less than about 5%, and in some embodiments, it means that the inactive component is contained in a trace amount below a certain reference value.
In some embodiments, the unit dose amount of dry powder retained in each drug compartment or dose container is less than 10 mg, typically about 5 mg, when treating lung diseases such as asthma. A mixture of less than a drug and lactose or other additives (eg, 5 mg LAC). Less than about 4 mg of pure insulin equivalent, typically about 3.6 mg of insulin may be given. The dry powder may be "compressed" or partially compressed and inserted into the dose container / drug compartment, or may be contained as freely flowing particles.
Some embodiments of the present invention are intended for inhalers capable of delivering a large number of agents that differ from each other for combinatorial delivery. Thus, for example, in some embodiments, some or all of the dose containers may contain two different agents, or different dose containers containing different agents may be administered substantially simultaneously. It may be configured to do so.
The inhaler may be configured to contain any suitable number of doses, typically about 30-120 doses, and more typically about 30-60 doses. .. The inhaler can deliver one type of drug or combination drug. In some embodiments, the inhaler has approximately 30-60 doses consisting of two different agents (which may have the same or different unit amounts), and thus in total. It may contain about 60-120 unit doses. The inhaler can supply the drug over a period of 30 to 60 days (or more). In some embodiments, the inhaler is configured to contain approximately 60 doses of the same drug or combination drug (which may have the same or different unit amounts). It may have been done. This allows the drug to be supplied for 30 days (when administered twice daily) and the drug for 60 days when treated once daily.
Some embodiments are particularly suitable for administering the drug to a respiratory patient, a diabetic patient, a cystic fibrosis patient, or a patient treating distress. This inhaler may be used to administer anesthetics, hormones, and / or fertility drugs.
This dose container assembly and inhaler are particularly suitable for administering drugs for the treatment of respiratory diseases. Suitable agents are, for example, analgesics, such as codeine, dihydromorphine, ergotamine, fentanyl, or morphine; angina preparations, such as zirchiazem; antiallergic substances, such as chromoglycate, ketotiphen, or nedocromyl; anti-infection. Drugs such as cephalosporin, penicillin, streptomycin, sulfonamide, tetracycline, and pentamidine; antihistamines such as metapyrrylene; antiinflammatory agents such as dipropionate bechrometazone, propionate fluticazone, flunisolide, budesonide, lofreponide, furoate mometazone , Or triamsinolone acetonide; antitussives, such as noscapine; bronchial dilators, such as albuterol, salmeterol, ephedrine, adrenaline, phenotelol, formoterol, isoprenaline, metaproterenol, phenilefurin, phenylpropanolamine, pyrubuterol, reproterol, limiterol , Isoetaline, salmeterol, or (-)-4-amino-3,5-dichloro-α-[[6- [2- (2-pyridinyl) ethoxy "hexyl] methyl] benzenemethanol; diuretics, such as amylolide; Anticholinergic agents such as ipratropium, thiotropium, atropine, or oxytropium; hormones such as cortisone, hydrocortisone, or prednisolone; xanthin, such as aminophylline, cholineteophilinate, lysineteophylline, or theophylline; It may be selected from therapeutic proteins and peptides, such as insulin or glucagon. If appropriate, these agents may be used in the form of salts (eg, as alkali metal or amine salts or acid addition salts) to optimize the activity and / or stability of the agents. It will be apparent to those skilled in the art that they may be used as esters (eg, low alkyl esters) or as solvates (eg, hydrates).
Some suitable embodiments of the dose vessel assembly and / or inhaler include albuterol, salmeterol, fluticasone propionate, and beclomethasone dipropionate, and salts and solvent products thereof such as salmeterol sulfate and salmeterol xinaho. Contains agents selected from the group consisting of acid salts. The agents may be delivered in combination. As an example of a particular formulation containing a combination of active ingredients, in combination with an anti-inflammatory agent such as beclomethasone ester (eg dipropionate) or fluticasone ester (eg propionate) (eg free group or sulfate). Examples include those containing salbutamol (as a salt) or salmeterol (eg, as a xinafoate).
The drawings will be described below. FIGS. 1A and 1B show an example of a multi-dose inhaler 10 having a cover 11 and an inhalation port 10p. The cover 11 extends over the upper surface of the inhaler, covering the suction port 10p of the mouthpiece 10m and extending downward, and then extending rearward from the mouthpiece 10m over the bottom surface of the inhaler. However, the configuration of this inhaler is shown solely for the purpose of integrity, and embodiments of the present invention are not limited to the configuration of this inhaler, but other morphological factors, other Covers, and other inlet configurations may be used.
FIG. 2A shows a dose vessel assembly 20 with a dose ring or dose disc 30 having multiple dose vessels 30c. As shown in FIGS. 2B, 2E, in some embodiments, the dose ring or dose disc 30 may include a plurality of circumferentially spaced through openings 30a. These openings 30a form part of the dose container 30c. As shown in FIG. 2E, the doze container 30c is defined by the doze container opening 30a and the upper sealant 36 and the lower sealant 37.
As shown, the dose vessel assembly 20 comprises a lower airway disc 40 and an upper airway disc 50. In other embodiments, the dose vessel assembly 20 may include only one dose vessel disc 30, a lower airway disc 40 or an upper airway disc 50. In such a configuration, on the other side of the disc 30, other types of airways, such as, but not restricted, fixed or widespread upper or lower airways, are on the upper or lower airway discs. It may be used with the individual airways brought about by either 50 or 40. It is also expected that the upper and lower airway discs 50,40 described herein will be used upside down (ie, carelessly, unusually) as in normal operation. ing. Specifically, it is also considered that the lower airway disc becomes the upper airway disc and the upper airway disc becomes the lower airway disc.
As shown in FIGS. 2A, 2B, the lower and upper airway discs 40, 50 each include a plurality of airway passages 41, 51 that are circumferentially separated. Typically, the discs 40,50 have one aisle 41,51 for one dose container 30c. However, in other embodiments, each airway passage 51,41 from one or both of the discs 50', 40', for example, as shown in FIG. 2C, has two or more different dose containers 30c. You may communicate with. This configuration allows (simultaneous) combined delivery of two or more different dry powders from one of the associated airway passages 51 or 41 and / or two or more dose containers 30c communicating with those airway passage pairs. It will be possible. Thus, embodiments of the present invention have been shown to release only the dose from a single dose container 30c during a single delivery, whereas in other embodiments there are two inhalers. The combination drug can be administered by using the respective airway passages 41 and 51 for delivery in the above dose container 30c.
The disc 30 is a double container 30c arranged in a straight line.<sub>1</sub>, 30c<sub>2</sub>It should also be noted that there may be a single doze container 30c separated in the circumferential direction in between. However, in some embodiments, the dose disc 30 is a double (or more) container 30c that is radially separated from each other along with the corresponding airway passage 41/51 (typically a passage pair).<sub>1</sub>, 30c<sub>2</sub>It is expected that it may be configured so that it does not require either a short passage 41,51 or a single dose container 30c, provided that it has. The dose vessels may be arranged in a straight line of pairs (or more) of concentric rows. In some embodiments, as a combination delivery configuration, a dose vessel 30c configured to be located below or above each airway passage 41/51.<sub>1</sub>, 30c<sub>2</sub>In this case, the airway passage 41/51 is staggered (relative to the inner circumference of the dose vessel) from the dose vessel near the inner circumference of the disc, as shown in Figure 2G. It may be inclined and extend toward the doze container near the outer circumference arranged in. However, one or more airway passages may extend above or below two or more dose passages with non-alternate centerlines.
In other embodiments, two or more dose discs 30 may be stacked, as shown in FIG. 2F. These dose discs 30 may be sandwiched between airway aisle discs 40, 50 or may be used in conjunction with a single orbit disc 40/50. In this case, the piercing tool opens each container of the two or more stacked doze discs, releases the drug from the two or more stacked doze containers, and uses one or two passages 41,51. It should be configured to allow inhalation.
In other embodiments, one dose vessel 30c is provided by different dose vessels that communicate with the respective airway passages 51, 41.<sub>1</sub>Releases dry powder into airway passages 41 and / or 51, then another dose container 30c<sub>2</sub>Can also re-release dry powder into airway passages 41 and / or 51. Thus, in embodiments of the present invention, some or all of the airway passages 41,51 can be used once or twice (and other configurations that are used more often) are possible. ).
In some embodiments, airway passages 41,51 are present in each airway passage once the inhaler has been reindexed to another position where the outer ring of the dose vessel is aligned with the airway disc. It defines an airway that prevents the dry powder from being released to the user. These passages (unless, as mentioned above, a two-use configuration is used and the airway passage may be used to release another dose only once) to prevent overdose. For this purpose, it may be configured to have a "sink trap" that prevents leakage according to some embodiments of the present invention.
If two airway discs, eg, both the lower and upper discs 40, 50, are used, the inhaler 10 can be operated even when the discs are inverted and have the same overdose protection. It can be configured to have. Leakage of dry powder from the inhaler 10 when the dose container 30c is opened may be affected by gravity. For example, in the case of a normal left-right semicircular quadrilateral or elliptical mouthpiece shape, there are two main device orientations (front side up and surface side down). The inhaler can be operated in any of these orientations. For example, in the embodiment shown in FIG. 2A, this is a target dose vessel 30c corresponding to an individual airway area for each dose vessel 30c (or multiple dose vessels if delivery of a combination drug is desired). It will be achieved by placing it both above and below.
2A, 2D, 3A show that the doze container disc 30 can include 60 doze containers 30c, and FIG. 3B shows that the doze container disk 30 can include 30 doze containers 30c. It shows that it can be done. More or fewer dose containers may be used.
FIG. 2E shows that the sealing layers 36, 37 should be configured as an annular flat ring. As shown, these sealants 36,37 can be used to seal the top and bottom surfaces of the dose disc 30. The sealing layers 36 and 37 may be made of the same material or different materials. Examples of sealing layers 36,37 include foils, one or more polymers and / or one or more elastomers, or other suitable materials, or combinations of these materials, such as laminates. Typically, the sealing layers 36,37 are thin flexible sealing layers made of foil.
Sealing layers 36,37 (if used) may be provided as substantially continuous rings as shown in FIG. 2E, or separate pieces that can be placed above and below the opening 30a. It may be attached to the dose container disc 30 as a band or spot piece of sealant. In other embodiments, the sealing layer may be provided on only one main surface of the dose disc 30. In this case, the opening 30a is not a through hole but is closed on one side (not shown). In yet another embodiment, the dose disc 30 may have a blister structure 130 (FIG. 17A).
FIGS. 2A, 2D, 3A, 3B also show that the dose container disc 30 can include at least one indexing notch 34. These indexing notches are illustrated as a plurality of indexing notches 34 that are spaced apart in the circumferential direction. One mating component of the other discs 40,50 can be used to assist in positioning the discs 30, 40, 50 with respect to each other. For example, one of the airway discs 40,50, typically the lower disc 40, may have an inner wall with tabs 45 (FIGS. 4A, 6) extending radially outward. The tab 45 is aligned with and engaged with one of the notches 34 in order to position the passages 41, 51 in a straight line with the dose vessel 30c. Other alignment means, eg, a configuration opposite to the notch / tab configuration described herein (eg, one or both of the airway discs 40, 50 have a notch and the dose container disc 30 is a tab or other component. A configuration having the above) may be used.
As shown in FIGS. 2B, 2D, 3A, 3B, the doze containers 30c may be arranged so as to be circumferentially separated from each other along one or more rows. As shown in Figure 3A, the dose vessels 30c are in alternating concentric rows, specifically the front row 31 at the first radius from the center of the disc and a second radius different from the first radius. It is located in the back row 32. The doze container 30c may be arranged so that the center line of the doze container 30c in the back row deviates from the center line of the dough container 30c in the front row by a certain distance in the circumferential direction. As shown in FIG. 3A, the dose vessels 30c in each row are separated from each other by a distance "D". The misalignment of the centerline of the doze container in the back row with respect to the centerline of the doze container in the front row is "D / 2". The dose container disc 30 may be a molded polymer, copolymer or mixture, and a derivative thereof, a metal or a combination thereof, or a material capable of providing sufficient moisture resistance. You may.
The dose vessel disc 30 can have an outer diameter of about 50 mm-100 mm, typically about 65 mm, and a thickness of about 2 mm-5 mm, typically about 3 mm. The disc 30 may be made of a cyclic olefin (COC) copolymer. The opening 30a can have a diameter of about 2 mm-5 mm, typically about 3 mm. Also (when the molding process is used to form the disc 30), to facilitate mold release, the side walls 30w of the dose container 30c are each about 1 °, as shown in FIG. 3D. Between -3 °, it is typically good to have an angle or tilt of about 1.5 °. The dose container 30 is configured to provide the desired number of doses for the overall size of the small inhaler and to protect the powder from moisture ingress. The individual dose container openings 30a are separated from each other to obtain sufficient sealing area and sufficient material thickness for moisture protection of the powder.
Similar to the embodiment shown in FIG. 2E, FIG. 3C shows that the dose vessel 30c is defined by an opening 30a sealed by sealing layers 36, 37 above and below the opening 30a. As mentioned above, the sealants 36,37 can include foils, polymers and / or elastomers, or suitable materials or combinations of materials, such as laminates. In the powder drug inhaler 10, the drug powder is stored in the enclosed moisture resistant space provided by the dose container 30c.
In embodiments of the present invention, there is a doze container assembly 20 that can provide a suitable seal and facilitate the attachment of airway discs 40, 50 by holding the doze rings or doze discs 30 between them. It is provided. As shown in FIGS. 2D, 2E, in some embodiments, the dose container disc 30 includes sealants 36, 37 forming a continuous layer on the upper and lower surfaces (main surfaces) of the dose disc 30. There is. The upper and lower airway discs 50 and 40 can be in contact with the respective sealants and can be in contact with the dose disc 20 so that they can be tightened and fitted. The exemplary mounting features shown in FIGS. 2A, 2E, 6 allow air leakage to be reduced by tightly fitting the airway discs 40, 50 to the dose ring 30. The discs 40, 50 sandwich the doze ring 30, and the doze ring can function as a "stop" that sets the engagement depth of the assembly features of the airway discs 40, 50. In the embodiment of the present invention, as described above, a feature portion for indexing and / or positioning the airway discs 40, 50 with respect to the dose ring 30 is provided. Additional or alternative, in some embodiments, relatively simple friction engagement members located on one or both of the airway discs 40, 50, as shown in FIGS. 2E, 4A, eg. Without limitation, the use of a "crush rib" 47r may allow the fixtures of the discs 40, 50 to be secured to each other, as described in more detail below. ..
FIG. 4A shows an example of the lower airway disc 40. As shown, the disc 40 defines a plurality of passages 41 separated in the circumferential direction. For staggered concentric doze vessel configurations, the disc 40 may include alternating long airway passages 42 and short airway passages 43. Each aisle 41 has an end portion 41a, 41b opposite to each other, specifically one (substantially or completely) closed end portion 41a, which is generally positioned adjacent to the dose vessel 30c, and. It has one open end portion 41b. The open end portion 41b is integrated with the outlet 10p and / or the mouthpiece 10m (Fig. 7A-7C) and / or the make-up air port or aisle and / or is located adjacent to it. The flow of intake air may be in either direction, and the open end 41b may be configured to face either the inner or outer circumference of the disc 40 (eg, the innermost or radial end of the disc 40). It should be positioned on the outermost side in the radial direction). The passage 41 comprises an upwardly extending side wall 41w, and a pair of long and short passages adjacent to each other share one of these side walls 41w. Optionally, all or some of the passages 41 may be provided with small air vents 48, as shown in FIG. 4A as features 48 that line up with some passages. The air vents 48 are sized to allow air to enter while preventing dry powder from flowing out of the air vents (how many air vents 48 are for ease of explanation). Shown only for that passage 41).
FIGS. 4A, 4B also show that the discs 40 can have tabs 47 extending upwards, spaced apart from each other in the circumferential direction. One of the tabs 47 may include a tab 45 extending radially (outwardly) as described above. The disc 40 may additionally or optionally (optionally) include a recess extending in the circumferential direction. The recesses are arranged straight side by side with the tabs of the upper airway disc 50 and are for sandwiching the dose disc 30 between them. The tab 47 may optionally include a crushing rib 47r. The rib 47r is designed to fit tab 57 of the upper airway disc 50 to hold the three-part dose assembly 20 with sufficient force without the need for any additional mounting means. ..
In Figures 4C, 18D, 20 the disc 40 is equipped with a dose mark 44 so that the user can visually see which dose is being administered or how much dose remains in the inhaler. It shows that it can also be done. The dose mark 44 may be arranged in line with the dose reading opening of the inhaler housing. This allows the user to visually check the doze mark / information that is visible to the naked eye when each dose is indexed to the administration position or the next time the dose is indexed to the administration position. The dose mark 44 may be additionally or alternatively placed on the upper disk 50 and aligned with the dose reading opening (FIG. 20), or the upper and lower airway disks 50, It may be located in both of the 40s. FIG. 18D shows that the dose marking 44 is located along the outer periphery of the lower surface of the lower disk 40 and is numbered 1-60. In some embodiments, as shown in FIG. 20, the number of mark 44 increases sequentially, alternating between rows of dose vessels 30, when the dose vessels are sequentially opened in alternating rows. It is good that it is attached like this. For example, the outer row doze containers can be numbered 1, the inner row doze containers can be numbered 2, the outer row doze containers can be numbered 3, and so on. On the contrary, it may be numbered). However, other dose numbering patterns may be used, depending on the arrangement of openings (and the number of doses on the disc). That is, this numbering is such that if two rows of doze containers are used, the inhaler opens one row of doze containers and then the adjacent doze containers in the other row (eg, on the inner ring). The doze container is opened alternately from the doze container to the outer ring doze container or from the outer ring doze container to the inner ring doze container), and it is suitable for repeating this opening order. However, in other embodiments, the inner row of dough containers or the outer row of doze containers may all be opened and then the other row of doze containers may be opened, or the inner and outer row of doze containers may be opened. It may be opened according to different alternating patterns. Therefore, in this case, the dose number may be marked on the disc 40 and / or 50 according to the order of such opening.
FIG. 5A shows an example of the upper airway disc 50. In this embodiment, the upper airway disc 50 is shown inverted (inverted with respect to the orientation shown in FIG. 2A) from its normal use position. As shown, the disc 50 defines a plurality of passages 51 separated in the circumferential direction. For staggered concentric doze vessel configurations, the disc 50 may include alternating long airway passages 52 and short airway passages 53. Each passage 51 includes end portions 51a, 51b that are opposite to each other. The closed or substantially closed portion 51a is typically located adjacent to the doze vessel 30c. The flow of intake air may be in either direction, and the open end 51b may be configured to face either the inner or outer circumference of the disk 50 (eg, the innermost or most radial direction). It should be positioned somewhere outside). The other (open) end portion 51b is integrated with and / or adjacent to the outlet flow path port 10p and / or mouthpiece 10m and / or supply air port or passageway. The passage 51 has a side wall 51w extending downward, and a pair of long and short passages adjacent to each other share one of these side walls 51w. Optionally, one or all of the passages 51 may be provided with a small vent hole 48, as shown by the dashed line with respect to the feature 48 in FIG. 5A (in the figure, for ease of explanation). (Shown only for some passages). The air vent 48 is sized to allow air to enter while preventing dry powder from flowing out of the air vent.
As shown in FIG. 5A, each passage 51 may include an opening 55. The opening 55 is configured to be located above each doze container 30c (straight with each doze container 30c). The upper sealing layer 36 of the dose container 30c is located below the opening 55. The opening 55 allows a puncture (eg, slice or puncture) mechanism to open the sealing layers 36,37 (FIG. 3C) through the opening. As shown in FIG. 5A, the upper disc 50 may also include one or more indexing ribs 58 and / or inner peripheral gear teeth 59 or other features. These features allow the disc to be rotated and indexed in the inhaler. Indexing will be performed to feed a different dose vessel 30c to the dosing position and / or to position the puncture mechanism on the target dosing vessel for administration in order to open the dose vessel 30c. .. In other embodiments, one or both (or different features) of these rotation / positioning mechanisms may be provided on the lower disc or dose disc (not shown).
FIG. 5B shows that the disc 50 may have three tabs 57 instead of the four tabs as shown in FIG. 5A (in this embodiment, the lower airway disc 40). Can also have 3 tabs instead of 4 tabs, see Figures 4B and 4C). One of the tabs 57 may have a vertically extending positioning tab 56 shown on the inner peripheral surface of the tab 57. The positioning tab 56 may be located on the upper disk 50 and may be configured to work with a puncture frame associated with a puncture mechanism fixed within the inhaler housing. Specifically, the positioning tab 56 is placed straight alongside the frame, sets the first exact position with a dose number (eg, 1), and the indexing is for the dose in the disk assembly 20. It is designed to prevent you from exceeding the number. In other words, the positioning rib 56 works with the inhaler housing or the components attached to it to set the initial position of the disc assembly 20 so that the disc assembly 20 is more than once (eg, for example). It should be used to stop the rotation (above 360 °). In other embodiments, these features are alternative features such as the dose counter described in U.S. Patent Application No. XX for co-pending sharing specified by Agent Docket No. 9336-38. It may be brought about by a part or an alternative component. It should be noted that this content is included here by reference as if it were completely described.
The indexing of the disc assembly 20 in the inhaler 10 is approximately 6 ° per dose (approximately 6 ° for each of the 60 doses that can be administered for 60 doses in one 360 ° revolution). can do.
FIG. 5B shows that the opening 55 may be configured to have a geometric shape corresponding to the shape of the piercing tool 100. The opening 55 may be configured to tightly surround the piercing tool 100 (FIG. 20). The piercing tool 100 can be a grooved piercing tool. As shown, the opening 55 accommodates three lobes 55l to tightly fit and accept the three lobe (grooved) piercing tools 111 (FIG. 19C / 19D) corresponding to the shape of the opening. Have. The grooved piercing tool may have another number of lobes, eg, four lobes 111'distant from each other in the circumferential direction, as shown in FIG. 19F, in which case the opening 55 It can have four corresponding lobe shapes. These lobes 55l can be oriented differently in the inner and outer rows, eg, 180 ° rotated (see Figure 20).
Figures 2A and 6 show the integrally mounted dose container assembly 20. Figures 2B, 4A, and 5A show exemplary disc components 30, 40, 50. The tab 57 of the disc 50 is fitted into the space 49 of the disc 40, the tab 47 of the disc 40 is fitted into the space 59 of the disc 50, and the crushing rib 47r (if used) is firmly attached to the outer edge of the tab 57. It will come into contact. This allows these parts to be sandwiched between them and frictionally engaged with each other for a flush fit by a relatively easy "press-fit" method. be able to. The dose vessel disc 30 is, as described above, via a tab 45 (extending radially outward) that engages with one of the alignment notches 34 of the dose vessel ring 30 to provide upper and lower airway discs. It will be arranged straight side by side. However, other mounting configurations may be used with other alignment features or other markings.
Upper and lower airway discs 50,40 (if both are used) may be attached to the dose vessel disc 30, or upper and lower airway discs 50,40 are drawn by these discs. Dose discs 30 may be sandwiched between them and mounted together so as to reduce the gaps in the airway pathways formed. The disc 30 can serve as a stopper for the mounting features of the airway discs 40 and 50. The disc 30 with the sealants 36,37 can have substantially flat upper and lower main surfaces without the need for any mounting features. The lower portion of the upper airway disc 50 and the upper portion of the lower airway disc 40 are placed snugly against the sealant and / or the main surface of the dose disc 30 on each dorsal main surface of the dose vessel disc 30. be able to. Therefore, mounting features / components are provided only on the upper and lower discs 50,40, which allows between the discs 30,40,50 without the gaps created by tolerances in other assembly structures. It can provide a sufficient airtight interface that is in close contact with the. This press-fitting installation, which provides a substantially airtight interface without the use of adhesives, is advantageous and cost effective. However, as mentioned above, other mounting configurations, such as ultrasonic welding, bonding, laser welding, other friction fitting and / or fitting configurations, and combinations thereof may be used. Also, there is a seal (O-ring, gasket, etc.) between the contiguous zone of the airway passage wall facing the dose vessel 30c and the sealing layers 36,37 above and / or below the dose vessel 30c of the disc. It may be used.
As shown in FIGS. 7A-7C, during operation, a pair of upper and lower passages 41,51 extending radially to each other are above and below each dose vessel 30c. positioned. These passages 41, 51 will communicate with each other through the opened dose container 30c and the opening 30a. That is, as shown in FIG. 7A, the puncture mechanism 100 advances and pierces the upper and lower sealing layers 36 and 37 (FIGS. 2E and 3C), respectively. The puncture mechanism 100 may be configured to project into the lower airway passage and be retained in the passage, or after opening the lower sealant and prior to administration (partially or completely). ) It may be designed to retreat. Further, although the state of projecting downward to pierce the sealing layer is shown, the piercing mechanism 100 may be configured to project upward from the bottom side. In any case, in some embodiments, the puncture mechanism 100 may be configured to close the opening 30a and / or the opening 55 of the upper disc (or lower disc).
As shown in FIG. 7B, the piercing mechanism 100 is then partially or completely retracted or protruding into the lower (or upper) airway passage, depending on the structure of the piercing mechanism. It will be put on hold. However, typically, the puncture mechanism 100 works with a member capable of closing the opening 55 of the upper disk 50 (or the lower disk 40 if pierced from the bottom) and / or closing the opening 55. As the puncture mechanism 100 and / or collaborative members act or block this passage 55 by substantially blocking, ie, blocking (and / or sealing) the hole / opening 55 (FIGS. 2A, 5). Is configured in. In this way, if the inhaler is inverted, the powder is prevented from leaking out of the passage 51 due to the obstruction provided by the puncture mechanism 100. The direction of the airflow path 10f may be from the top to the bottom of the dose container 30c, or vice versa. The direction of the airflow 10f with the dry powder may be from the inner circumference to the outer circumference, or vice versa. Figures 7B and 20 show the direction of the exemplary airflow path 10f (indicated by the arrows). Through this airflow path 10f, air flows in from the opening 41b of the bottom passage on the outer circumference of the disc assembly 20, passes upward through the opening 30a, and flows from the opening 51b of the upper passage 51 of the disc assembly 20 to the mouthpiece 10m. become. Both the exit or open end portions 41b, 51b of the aisle may face the inner circumference of the disc assembly 20 rather than the outer circumference as shown in FIGS. 7A-7C (see, eg, FIG. 17A). Please also note that.
After administration, the puncture mechanism 100 retracts completely, the dose vessel assembly 20 is rotated to the dosing position, and / or the puncture mechanism 100 opens a different dose vessel 30c, as shown in FIG. 7C. Will be operated to do. During operation, the dose vessel assembly 20 seals or adheres to the airway passages 41 and / or 51 with, for example, the outlet flow path member 10fm that is united with the mouthpiece 10 m. It may be pushed outward in the radial direction to bring it.
Figure 17A shows that a seal 129, such as an O-ring, may be used to provide a sufficient airtight path between the airflow outlet 10l (or short path 10s and / or mouthpiece 10m) and the disc assembly 20. Is shown. Sealed or blocked configurations of outlet airflow paths on other discs may be used. These examples will be described below.
In some embodiments, the partial retraction of the piercing tool 100 can prevent or prevent the powder from falling out of the airway passage when the inhaler 10 is used in the inverted position. For example, as shown in FIGS. 17A, 17E, the gap between the piercing head 100h and the access opening 55 of the upper airway disk 50 should be small to facilitate this operation, and / Or it should be designed to fit the piercing head 100h exactly. The piercing mechanism 100 may be configured to be operated with a high level of positioning accuracy. Specifically, the piercing tool 100 is straight with the access opening 55 of each dose container 30c held by the disc 30 (arranged in each row, typically alternating between rows). It may be configured so that they can enter the access opening side by side in an efficient manner. In some embodiments, by reducing or eliminating air leaks at the junction 10j (FIGS. 17A, 17E) between the fixed airway associated with the mouthpiece 10m and the rotating rotating disk subassembly 20. It is possible to deliver a constant dose, and if there is a leak, the leak can be constant between the doses. This function can be achieved by using the follow-up seal 129 as described with respect to FIG. 17A. Further, as described above, the disc 20 may be urged toward the mouthpiece 10m (for example, may be pushed radially toward the joint 10j / mouthpiece 10m).
FIG. 17B-17E shows an embodiment of an inhaler 10 in which the disc assembly 20 can be urged towards the mouthpiece 10 m using the lever assembly 80. This urging can facilitate accurate and repeatable positioning of the disc assembly 20 for puncture and control air leaks at the mouthpiece joint 10j. With respect to air leaks, in the inhaler embodiment, the tight connection between the disc and the mouthpiece is temporarily synchronized with the time of inhalation and at other times, eg, during indexing of the disc assembly 20. The inhaler is designed to allow a loose fit to facilitate rotation of the disc assembly 20 within the inhaler 10. In this embodiment, the mouthpiece 10 m is arranged on the outer circumference of the disc assembly 20, and the outlet of the disc assembly 20 is also arranged on the outer circumference of the disc assembly 20. In other embodiments, the outlets of the airway passages may be located on the inner circumference of the disc, or may be otherwise configured, or may be otherwise located.
As shown in FIG. 17B, the lever assembly 80 includes a lever arm 81 that works with the top surface of the upper airway disc 50. The lever arm 81 extends downward at a distance from the outer circumference so as to be close to and separated from the outer circumference of the disc assembly 20. The lever assembly 80 also includes a finger portion 82. The finger portion 82 is located above the disc assembly 20 and extends downward toward the disc assembly 20. In the illustrated embodiment, the lever assembly 80 also comprises a load post 84. The load post 84 is located near the perimeter of the disk assembly 20. The lever arm 81 includes a recess 83 configured to receive the finger portion 82. When the finger portion 82 is located in the recess 83, the post 84 pushes the disc 20 inward in the radial direction, creating a tight joint 10j during suction (FIG. 17E). The recess 83 can have an open peripheral shape, and the finger portion 82 can slide in and out of the recess. The lever arm 81 can define a slope (inclined towards the recess 83). This slope is slidably engaged with the finger portion 82, which can guide the finger portion 82 to move toward the recess 83.
The finger portion 82 of the lever assembly is attached to the lever 12n (numbered 10l in Figure 1B), typically in the inhaler housing when the lever 12n is activated by the user. , It is designed to rotate with respect to the frame 12. When the lever 12n returns from the "actuated (administration)" position, the finger portion 82 is pulled out of the recess 83, which allows the disc assembly 20 to rotate freely to index to the next administration position. Can be done.
Typically, during inhalation, the load post 84 is located radially opposite the mouthpiece 10 m (substantially opposite in the radial direction). The lever arm 81 and the post 84 do not rotate. This component is attached to a frame 12 attached to the inhaler housing. The finger portion 82 will rotate with respect to the frame 12 (and the lever arm 81).
As shown in FIG. 17B, the finger portion 82 is no longer in contact with the lever arm 81 during this period of the lever assembly 80 movement cycle to allow free rotation during indexing. There is. FIG. 17C shows a finger portion 82 moving toward the recess 83. FIG. 17D shows a finger portion 82 located in the recess 83 and urging the disc assembly 20 towards the outlet flow path member 10fm. At the time of inhalation, the finger portion 82 advances to its maximum movement limit. While the disc assembly 20 is indexed (rotated), the finger portion is located somewhere in its movement path (the arm is stationary). Therefore, as indicated by the arrows in FIG. 17D, the lever assembly 80 has the finger portion 82 moved farthest at the appropriate time (during inhalation), urging the disc assembly 20 and joining. The 10j is sealed, while allowing its free movement during indexing (typically except during inhalation) without urging the disc assembly 20.
During manufacturing, it has been found that an error-induced inconsistency can occur between the diameter of the dose disc 30 of the disc assembly 20 and the diameter of the upper airway disc 50. As shown in FIG. 17E, when the disc assembly 20 is urged to the mouthpiece 10 m, the inner or outer side wall surfaces of both of these discs 30, 50 (shown as the outer side wall surfaces in the figure). Will come into contact with the mouthpiece 10m. Therefore, as shown in FIG. 17E, if the upper airway disc 50, which has a larger contact area, is always in contact with the mouthpiece or outlet flow path member 10mf communicating with the mouthpiece 10m, the dose At the point where it overlaps with the disk 30, a small relief 10r occurs in the form of being cut into the proximity surface or the contact surface of the outlet flow path member 10fm (which may be the mouthpiece 10m) or other forms. There is.
17F, 17G show an alternative embodiment of the urging mechanism 180. The urging mechanism 180 now urges the disc assembly 20 towards the mouthpiece 10 m during inhalation and then is released or disengaged to allow rotation of the disc assembly 20 for indexing. ing. As mentioned above, in some embodiments, the inhaler 10 is for continuous dosing from the alternating doze containers in the inner and outer rows, or for continuous access to the doze containers. It may be configured to rotate the disc assembly 20 by a specified angular rotation, eg, about 6 °. The urging mechanism 180 may be configured to be operated by a lever 10l similar to the lever described above with respect to the lever assembly 80, but may be actuated using other components or features. You may.
As shown in FIG. 17F, the urging mechanism 180 may include a post 182 located near the inner circumference of the dose vessel disc assembly 20. The post 182 may be arranged in the elongated hole 182s extending in the circumferential direction. The elongated holes 182s have an end portion integrated with an elongated hole portion 183 extending radially outward toward the inner circumference of the dose disk assembly 20. During and / or shortly before the release of the drug to the user for inhalation (eg, "dosing"), the post 182 moves within the long hole 182s until it reaches the long hole portion 183. Within the slot 183, the post (typically indirectly) pushes the inner circumference of the disc assembly 20 (as indicated by the arrow) and pushes the disc assembly 20 towards the mouthpiece 10 m. It will be urged. The inhaler in FIG. 17F is shown inverted from the normal orientation.
FIG. 17G shows that the post 182 may be interlocked with a stationary post 182b on the indexing plate or frame 184. In the illustrated embodiment, the urging post 182 is configured to flex the post 182b radially outward with respect to the dose vessel assembly 20 by contacting and pushing the post 182b. The two posts 182,182b may be configured to project toward each other, specifically, one projecting upward and the other projecting downward. The post 182b is typically located close to the inner circumference of the dose disk assembly 20.
The post 182 is typically attached to or interlocked with a lever 10l that is accessible to the user. However, the post 182 may be interlocked with other mechanisms that move the post 182 within the elongated holes 182s to urge the disc assembly 20 towards the mouthpiece 10 m.
As shown in FIG. 17G, the indexing plate 184 may be located below the gear 109g associated with the indexing device 109. The rotary gear 109g may be held by the mount 110 on the frame member 109f, as shown in FIG. 18E. In general, the gear 109g is on the teeth 109t on the indexing post 109p (which can be part of the slope disc 209 in FIG. 18F), and on the disc assembly 20 (eg, lower as shown). It is linked to the gear tooth 59a on the disc 40). By rotating the indexing post 109p, the gear 109g is rotated, which results in indexing the disc assembly 20. The other gear teeth 59b (located near the bottom of the inhaler housing) should be interlocked with the indexing control arm 109r shown in Figure 18D, which allows the dose vessel assembly to rotate as much as desired. Only can be rotated more accurately. Note that Figures 18D and 18E show the inhaler in an inverted orientation from its normal use orientation. FIG. 18F shows the inhaler in a "normal" use orientation, in which the dose disc assembly 20 is below the puncture mechanism 100, for example, as also shown in FIG. 18C. positioned. The piercing tool 100 may be interlocked with a slope disc 209 having a fin-shaped slope 211, as shown in FIG. 18F. In the illustrated embodiment, the slope disc 209 works with the piercing tools 100a, 100b to push the piercing tools 100a or 100b into the dose container 30c, respectively. The post 182 is typically attached to a lever 10l that is accessible to the user, as shown in Figures 17F, 18E, 18F. However, the post 182 may be interlocked with other mechanisms that move the post within the slot 182a to urge the disc assembly 20 towards the mouthpiece 10m.
The indexing mechanism 109 shown in FIGS. 17F and 17G will be described later with reference to FIG. 18C-18F. However, other indexing structures may be used.
FIG. 19A shows an embodiment of a piercing mechanism 100 having a corkscrew piercing tool 110. During operation, the corkscrew typically moves straight up and down in the vertical direction without rotation, producing the desired opening shape (eg, circular shape) that penetrates the sealing layers 36,37. ing. In other embodiments, the corkscrew may be designed to project and / or rotate during administration. In the illustrated embodiment, the corkscrew piercing tool 110 is held in the lower passage 41 and attached to the corkscrew 110 up and down together while the dry powder is being fed into the airflow passage. The opening 30a is closed by the moving elastic member 120. The piercing mechanism 100 is designed to perform a two-step operation, that is, a sufficient ascending step operation (for indexing) and a sufficient descending step operation. The foremost portion of the corkscrew can have a shaped tip that gives the sealant (eg, foil) the desired cut shape. In some embodiments, the corkscrew piercing tool 110 cuts out a shape having ears on sealants 36, 37, which is then bent downwards to release dry powder. By retaining the corkscrew piercing tool 110 in the passage 41 during administration, improved aerodynamic turbulence, shear turbulence, or impact turbulence can be brought to the dry powder. The elastic member 120 may be composed of a foam block or other elastic member (eg, a hard or rigid member urged by a spring) that can be used to seal or close the opening 30a. FIG. 19B shows a similar corkscrew piercing tool 110 used with a disc assembly 20 having both upper and lower airway discs 50, 40. Elastic and / or flexible members 100p, such as polymer plugs and / or elastomer plugs or foam plugs, can be used to occlude or seal the disc opening 55.
19C and 19D show a piercing mechanism 100 having a grooved solid piercing tool 111. The groove may have a straight groove shape, or may have a twisted or partially twisted portion along its length. In the latter case, for example, it is preferable to have a twisted structure in which the maximum and minimum values of the lobe change in the axial direction along the length of the groove. The groove can have a cross section with multiple lobes, typically three or four lobes, eg, three lobes, as shown in FIG. 19C. The grooved structure is designed so that only a partial anterior length is projected, as shown in FIG. 19E, which partially occludes or seals the opening 55. It should be integrated into a constant diameter area for facilitation. In other embodiments, the structure of the solid or grooved piercing tool is to be integrated with a cap or plug 100p (see, eg, FIG. 19C) located over and / or within the opening 55. It may be. In some embodiments, the twisted groove 111 is to be retained within the dose vessel opening 30 and / or the lower disc 40 during administration, thereby causing turbulence and / or impact in the airways. Can be promoted.
FIG. 19D shows that the grooved piercing tool 111 can form a round hole by rotating when piercing foil or other sealing material, or may be projected straight without rotation. There is. In other embodiments, the grooved piercing tool 110 may be adapted to pierce one or more sealing layers 36,37 by projecting or advancing without rotation. In Fig. 19E, the grooved piercing tool 111'has a length of "L".<sub>1</sub>The grooved front portion 111f having "" is provided, and this grooved front portion 111f has a length of "L".<sub>2</sub>It is shown that it is integrated with the solid portion 112 having a substantially circular cross section having a. L<sub>1</sub>Is typically L<sub>2</sub>Is longer than. Length L<sub>1</sub>With the solid portion engaged to the airway disc opening 55, the grooved anterior portion 111f is held in the opening 30a of the dose vessel and / or at the same time in the lower sealant 37. Can be long enough (typically held just below the lower sealant or at the same height as or slightly above or below the underside of the disc 30). ..
FIG. 19G shows a piercing mechanism 100 capable of having a plug 100p (similar to that shown in FIG. 19B of a corkscrew structure) capable of blocking passage 55. The plug 100p may be used with any piercing tool, such as a corkscrew 110 (Fig. 19A) or a solid grooved piercing tool 111 (Fig. 19B), or any other piercing tool. The puncture head may be retained in the inferior passage 41 during administration, as shown in FIG. 19E. Alternatively, the piercing tool may be designed to partially retract through the passageway of the plug (not shown), leaving the plug 100p in place with respect to and / or above the opening or passage 55. Good.
In some embodiments, the grooved piercing tool 111 may be configured to have a lobe twisted along its length (Fig. 19D). For example, the grooved piercing tool 111 can have a twist of about 60 ° along its length so that it swivels around the lobe of the grooved piercing tool. During a straight piercing stroke (going straight to the sealant), the twisted grooved piercing tool 111 can make a perfectly round hole in the sealant 36 and / or 37.
FIG. 20 shows a substantially U-shaped air path provided by the disk assembly 20. The "U" shape is formed by the upper disk passage 51 and the lower disk passage 41. Specifically, these passages 41 and 51 define the long side of a "U-shape" extending in the radial direction across the disk body. As shown, in this embodiment, the outer circumference of the disk assembly 20 has both an outlet and an inlet for the airflow path 10f. The "U-shaped" flow path (or, in some embodiments, a partial "U-shaped" flow path if one of the airflow discs 40,50 is used) is the deagglomeration of the powder. It can function as a vessel. As the particles exit the dose vessel 30c, they collide with the opposing walls of the airway disc passage 51, resulting in sufficient force to deagglomerate the drug powder.
FIG. 20 also shows an example of the orbital 10d of dry powder particles associated with the airflow associated with the intake airflow path 10f. After the dry powder exits the doze vessel 30c into the airflow path 10f, the airflow and small powder particles in the air (10f) can rotate about 90 °, while the heavy dry powder particles (10d) are on the upper airflow disc. It will bounce off the inner wall 51w of the passage 51. The angle of this bounce gradually decreases, and the heavy dry powder particles eventually become almost straight out of the mouthpiece 10m. The collision of heavy dry powder with the wall 51w will promote the deagglomeration of the dry powder. Referring again to FIG. 5A, in an embodiment in which the dough containers 30 are arranged in two rows, the aisle 51 is located in the aisle 51 depending on whether the doze containers 30 are arranged in the inner row or the outer row. The lengths are different.
In some specific embodiments, the airway passages 41,51 include alternating short and long passages (see, eg, FIG. 5A). Long passages (in these passages, the dose container is located on the inner circumference if the outlet is located on the outer circumference, and the dose container is located on the outer circumference if the outlet is located on the inner circumference. The length can be between about 5 mm and about 15 mm, typically about 10 mm. The length of the short passage can be between about 3mm-10mm, typically about 5mm (eg about 40-70% of the length of the long passage). The depth (vertical height) of each passage 41,51 can be the same and may be different in some embodiments. An exemplary depth of passages 41,51 is between about 1 mm and 3 mm, typically about 2 mm, but other depths may be used.
The inhaler 10 can include actuators that the user can access, such as levers, knobs, switches, sliders, cranks, push buttons, or other mechanical and / or electromagnetic devices. The actuator rotates the assembly 20 to place one or more dose vessels 30c (Fig. 2B) in the dosing position within the suction chamber that communicates with the suction port 10p (Fig. 1B). Alternatively, the dose disc 30 can be indexed and / or (as described further below), the puncture mechanism 100 (FIG. 7A-7C) opens the front row dose vessel 30c and then the back row dose vessel. The 30c is opened (or vice versa), which allows the drug to be released into the inhalation airflow path for inhalation by the user. A sealed dose container 30c will be opened and connected to the airways 41 and / or 51 to release the inhalation powder. The airways 41 and / or 51 are connected to an outlet channel member 10fm, which may be an inhaler mouthpiece 10m (see, eg, Figure 7A-7C, 17A, 17E, 18A) or to the inhaler mouthpiece 10m. It is integrated. When the drug enters passage 41 or 51 (depending on how the inhaler is oriented), this passage is referred to as the "used" passage. The drug in the passageway will be delivered (if the user inhales properly and in a timely manner) and (if the user does not inhale and closes the mouthpiece or disassembles the disc assembly 20). It will be quarantined (if it is determined). The "use" passage is indexed with the opened dose container 30c and, as a result, cannot be used again. However, only for other dose vessels in the shared aisle (as described for Figure 2C), the aisle will be used again. Any powder remaining in the opened doze container is separated from the airways when the next doze container is indexed in place.
In some embodiments, the portion of the airway provided by the airway passage 41 or 51 adjacent to each dose vessel 30c is unique to that individual dose vessel 30c. Therefore, any outflow of powder into the airways is only available to the mouthpiece and the user as long as the dose container is indexed and connected to the main airway (mouthpiece). Upon indexing into the next dose vessel, adjacent (unconnected) airway sections are indexed into the active inhalation airway pathway, which causes powder to drain and / or accumulate in the airway sections.
8A, 8B show other embodiments of the inhaler 10. In this embodiment, the upper airway passage 51 may be configured as a path for a "sink trap" 51t. This path has a portion of the airflow path that rises and then descends or vice versa. That is, as shown, the path 51t rises above the opening 30a and then changes to extend downward over a distance, thereby adding dry powder from the airway / inhaler. Will bring about outflow resistance. Similarly, the lower airway passage 41 may be configured to form a "sink trap" 41t path by rising over a distance downstream of the dose vessel opening 30a. In some embodiments, only one of the airway discs (eg, upper or lower airway discs 50,40) has a sink trap, but in other embodiments, as illustrated. , Both disks 40,50 are designed to have an airway structure with sink traps 41t, 51t. The dose vessel assembly 20 has a pair of straight passages 41,51 that communicate fluid with each other when the dose vessel 30c is opened. A pair of these passages 41,51 is located above and below each dose container 30c and has a sink trap structure 41t, 51t. The sink trap structures 41t and 51t work together to form a curved (for example, laterally approximately S-shaped) airflow path. The airflow path 10f may extend from the outer circumference to the inner circumference, or may extend from the inner circumference to the outer circumference.
As shown in FIGS. 8A, 8B, in this embodiment, the piercing mechanism 100 can have two piercing members 100a, 100b. One piercing member is designed to open the first row of the dose container 30c, and the other piercing member is designed to open the second row of the dosing container 30c.
Figures 9A-9C, 10-14 show an exemplary inhaler structure with upper and lower airways forming a sink trap 51t, 41t airflow path according to an embodiment of the invention. As shown, the piercing mechanism 100 can include two piercing members 100a, 100b attached to a housing that slides over the dose vessel assembly 20'. The dose vessel assembly 20'can rotate below the puncture mechanism 100 so that each dose vessel 30c is indexed to the dosing position. Similarly, the dose vessel assembly 20'can rotate above the puncture mechanism if the puncture mechanism is located below the dose vessel assembly 20,20'.
Figures 10, 12, and 14 show the lower airway disc 40 with the upper member 40u and the lower member 40l attached so as to define two components, specifically a curved sink trap path 41t. It shows that it can be prepared. Similarly, the upper airway disc 50 can include two components mounted to define a curved sink trap path 51t, specifically the upper member 50u and the lower member 50l. In certain embodiments, the dry powder is supplied as a pre-weighed dry powder 200 and may be sealed within the opening 30a between the sealing layers 36, 37. As shown in FIG. 10, the upper member 50u can include a tab 150t. The tab 150t is adapted to engage the elongated hole 150s of the lower member 50l of the airway disc 50 for alignment and / or mounting.
FIG. 12 shows the doze vessel 30c in the outer row 31 (opened by the piercing member 100b) and the associated curved airflow paths 41t, 51t. FIG. 14 shows the piercing member 100a at the position of opening the dose container 30c in the inner row 32, together with the associated airflow paths 41t, 51t.
FIGS. 15A, 15B, 16 show an example of a doze container disc or ring 30 with two rows of openings 30a used in the doze container 30c. The dose container disc 30 can be relatively thin, for example, to a thickness of about 2 mm-4 mm. The opening 30a of the dose vessel is configured such that the inner row 32 is at least about 2 mm away from the outer row 31 and the inner and outer rows of the dose vessel are separated inward by about 2 mm from their respective perimeters. It is good. This interval will provide sufficient moisture permeability and / or oxygen resistance.
FIG. 17A shows an embodiment of the inhaler 10 having a long outlet air path of 10 l as compared to the short channel in FIG. 18A. In this embodiment, the airway disc is oriented with passages 41, 51 such that the open ends 41b, 51b open toward the inside of the disc rather than the outside. FIG. 17A also shows that the dose container disc 30 may be configured to have a blister 130.
FIG. 17A also shows that the piercing mechanism 100 may include a rotating piercing tool head 102. The rotary piercing tool head 102 is configured to pierce the dough container 30c in the inner row and then rotate to pierce the adjacent doze container 30c in the outer row.
FIG. 18A shows that the inhaler 10 may be configured to have a puncture mechanism 100. The piercing mechanism 100 moves radially to open one row of doze containers 30c, then moves inward or out of the radius to open the other row of doze containers 30c. There is. One or more of the dose vessel assemblies 20 and / or airway discs 40,50 and the dose vessel discs 30 are axially or otherwise (together or individually) to provide sufficient tight sealing, as described above. In the direction, it may be configured to be urged to one or more walls of the outlet airflow path. Figures 18A and 18B also show that the inhaler 10 can be equipped with an indexing mechanism 109 that works in concert with the gear teeth 59 on the inner circumference of the upper disc 50. Other indexing mechanisms may be used to rotate the assembly 20 and place the different dose vessels 30c in the dosing position.
FIG. 18C shows that the inhaler 10 may be configured to have a piercing mechanism 100 with two piercing tools 100a, 100b. One of the piercing tools 100a and 100b is designed to pierce the dough container in the inner row, and the other is designed to pierce the doze container in the outer row. Typically, the piercing mechanism 100 is configured to pierce the outer or inner row of dough containers and then pierce the other rows of doze containers. The piercing tools 100a and 100b reciprocate up and down to open their respective dose containers. One or more of the dose vessel assemblies 20 and / or airway discs 40,50 and the dose vessel discs 30 are outlet airflows (together or individually), axially or otherwise, to provide sufficient tight sealing. It may be configured to be urged by one or more walls of the path.
FIG. 18C-18E comprises an indexing mechanism 109 with a gear 109g in which the inhaler 10 works with the indexing post 109p, with the gear teeth 59a of the disc assembly 20 located on the inner circumference of the lower disc 40. It also shows that. FIG. 18D is shown inverted from the orientation during normal use shown in FIG. 18C. Figure 18C-18E also shows that the lower airway disc 40 can have two gear teeth 59a, 59b stacked in close proximity. One gear tooth 59a is designed to work with the post 109p and the associated indexing gear 109g. The other gear tooth 59b is capable of providing more precise positioning using the arm 109r, as shown in FIG. 18D. Other indexing mechanisms may be used to rotate the assembly 20 and place the different dose vessels 30c in the dosing position. The double piercing tools 100a and 100b can cooperate with the slope of the slope disc 209. The slope disc 209 can have fins 211 displaced circumferentially on two concentric rows. These fins 211 push their respective piercing tools downward by contact with the fins. A further description of the indexer and double piercing tool is set out in US Patent Application No. XX for co-pending sharing specified by Agent Docket No. 9363-38. This content is incorporated herein by reference as if it were fully described.
In some embodiments, the mouthpiece port 10p and the air inlet (not shown) may be separated from each other by a distance between about 12 mm-127 mm (about 0.5 inch-5 inch). The inhaler 10 (assuming measurements are taken from where the intake port is located to the intake port 10p) has a relatively short intake path, eg, as shown in Figures 7A-7C, 18A, 18C. With an intake passage between about 12mm-25.4mm, or a long air passage as shown in Figure 17A, typically an air passage between about 50mm-127mm (about 2 inches-5 inches). Good. A short air path extends between the dry powder release location and the inhalation mouthpiece (with a turbulence-promoting segment that prevents agglomeration that is united with the inhalation mouthpiece (not shown)). It should be defined to include a tubular air passage. The long air path may extend across the main part of the inhaler, i.e., substantially all of the width or length of the inhaler. The inner surface / shape of the flow path can be polygonal to facilitate the rebound of the swirling airflow on the inner surface that acts as the impact surface. For further study of suitable turbulence facilitating structures, see International Application No. PCT / US 2005/032492 entitled "Dry Powder Inhalers and Related Devices and Methods to Prevent Aggregation".
The inhaler 10 can have a body with a relatively small "pocket-sized" structure that is portable. In some embodiments, the inhaler body is less than about 115 mm (about 4.5 inches), typically less than about 89 mm (about 3.5 inches) wide / length, and less than about 51 mm (about 2 inches), Typically, it can have a thickness / depth of less than about 38 mm (about 1.5 inches). The inhaler body can also be configured so that the main surfaces facing each other are substantially flat so that they can be easily held in the pocket.
The inhaler may include circuits that can control some operations of the inhaler 10. The inhaler 10 may include a computer port (not shown). This port may be, for example, an RS232 port, infrared data communication (IrDA), or universal serial bus (USB). These are used to download or upload selected data between a computer application such as a clinician or other site or a remote computer and an inhaler. The inhaler 10 is configured to be able to communicate with the clinician or pharmacy and / or patient compliance for reordering the drug via a wired or wireless (one-way or two-way) communication link. You may. The inhaler 10 may include a communication port (not shown) for a second peripheral device. The inhaler 10 may be capable of communicating via the internet, telephone, mobile phone, or other electronic communication putrocol.
In some embodiments, the circuit may include computer program code and / or computer applications. These communicate with additional data or users (optionally the display) and / or with other remote devices, as described above (the term "remote" is used. , Refers to communication with devices that are present in the area during normal inhalation use, but are usually not connected).
In some embodiments, the circuit may be adapted to communicate with a vibrating device (not shown). The vibrating device may be any suitable vibrating mechanism. The vibrating device may be configured to vibrate the dry powder in the airflow path. In some embodiments, the vibrating device can include a transducer configured to vibrate one or more open cartridges holding dry powder. Examples of vibrating devices are, but are not limited to, (a) super-with an audible wavelength or higher or less that can be used to momentarily apply a non-linear pressure signal to the dry powder. Sound waves or other acoustic or sound sources, (b) electrical or mechanical vibrations of the walls (side walls, ceilings, and / or floors) of the suction channel, such as magnetically induced vibrations (using electromagnets or permanent magnets) and / Or deflection, (c) solenoids, piezoelectrically actuated parts, etc., (d) one or more of oscillating or pulsating gases (airflows) that change one or more of the volumetric flow, linear velocity, and / or pressure. Be done. Examples of mechanical and / or electromechanical vibrating devices are described in US Pat. Nos. 5,727,607, 5,909,829, and 5,947,169. These contents shall be included here by reference, as if all were cited. A combination of various vibration mechanisms may be used.
In some embodiments, an example of a vibrating device is a small transducer with part number QMB-105PX commercially available from Star Micronics (Shizuoka). This transducer has a resonance frequency in the range of about 400-600 Hz.
In some embodiments, the inhaler 10 may include a visible sign (blinking light, "error" indication, or visible warning) and / or the dose is properly (and / or inappropriate) from the inhaler. It may be configured to provide an audible warning to the user that it has been inhaled or released. For example, some dry powder doses may have their dimensions adjusted to make it difficult for the user to know the inhalation of the drug (usually the doses are aerosolized, almost or completely tasteless and / Or it will enter the body without touching it). Therefore, sensors (not shown) may be configured to communicate with the flow path of the inhaler and communicate with a digital signal processor or microcomputer located inside or outside the inhaler. During operation, the sensor is configured to detect selected parameters, such as weight differences, density of outlet aerosol components, etc., thereby confirming that the dose has been released. Good.
The sealed doze container 30c has a water vapor transfer coefficient of about 1.0 g / 100 inches.<sup>2</sup>Less than 24 hours, typically about 0.6g / 100inch<sup>2</sup>It is less than 24 hours and can be configured such that the oxygen transfer coefficient is suitable for the dry powder held in the dose vessel. The dose vessel assembly 20,20'can be configured to have a stable shelf life of about 1-5 years, typically about 4 years.
Doze container 30c is about 24mm<sup>3</sup>Less than, typically 5-15mm<sup>3</sup>Can have a volume between (filled and unsealed). The bulk density of the powder is about 1 g / cm<sup>3</sup>And the nominal density of the powder when filled (as a reference) is about 0.5 g / cm<sup>3</sup>Can be. The maximum compression of the drug by filling and sealing the dose container 30c can be less than about 5%, typically less than about 2%. Maximum heating of the drug during filling and sealing should be maintained at the desired level so as not to adversely affect the effectiveness of the drug or formulation.
FIG. 21 shows an exemplary operating process used to operate an inhaler according to an embodiment of the present invention. The device is configured to have an automated three-step operational manipulation process to prevent overdose. For example, the device (a) pierces the sealing layer, (b) releases the drug (typically the drug is delivered to the user shortly thereafter), (c) the next (not yet). Continuously manipulate or (a) with the target to index the doze container (which has been opened) (thus, if not inhaled, isolate or close any outlet path for the released dry powder). Index the doze container to be used (thus isolating the already open airway passage), (b) pierce the sealing layer, and (c) continuously release the drug or dry powder from the opened doze container. Can be operated as a target. A doze container ring having a staggered concentric arrangement of doze container openings sealed by the upper and lower sealing layers that define the doze container, one for each doze container and a plurality of circumferentially isolated rings. Provide a dose vessel ring attached to the lower disc with the airway passage (block 300). Rotate this dose container with the lower disc to the dosing position within the inhaler (block 310). The indexing mechanism can rotate the dose disc assembly by about 6 °. By repeating this rotation about 60 times, it is possible to access about 30 doze containers in the inner row and about 30 doze containers in the outer row with only about 360 ° rotation. The airway passages associated with the released dry powder are isolated from the inhalation pathways, so that the airway passages used are not used for any subsequent inhalation delivery or are used only once again. Becomes (block 325).
In some embodiments, the puncture mechanism is advanced to open both sealing layers and allow the dry powder to be discharged from the doze vessel at the dosing position into the lower airway passage (block 320). The puncture mechanism may be held in a protruding state, or may be partially or completely retracted with the puncture mechanism or its cooperating members blocking the opening to the upper airway passage. In some embodiments, the puncture mechanism may be partially retracted, leaving at least the anterior portion in the doze vessel opening, which is occluded and / or closed. The isolation step may be performed according to or / or to the step (block 350) or rotation step (block 310) of completely retracting the puncture mechanism from the doze vessel opening.
The method may optionally include directing the released dry powder fluidly to the user through the airway passages.
FIG. 22 shows an exemplary manufacturing process used to assemble a dose container assembly according to an embodiment of the present invention. As shown, a doze container disc with perforated openings separated in the circumferential direction is provided (block 400). At least one sealing layer is placed over the top or bottom of the dough container opening and attached to the upper or lower main surface of the disc (eg, a sealing layer in the form of a continuous layer, strip, or piece is placed over the opening. Can be) (block 410). Fill the doze vessel opening with dry powder (note that "filled" does not necessarily mean to fill volumetrically) (block 420). Typically, the openings are to be filled with about 30% -75% by volume powder. A sealing layer is attached to the other main surface of the dose disc to provide a sealed dose container (block 430). Place the dose container disc between the upper and lower airway discs (block 440). Place the dose vessels in a straight line so that they communicate with the airway passages separated from each other in the circumferential direction of the airway discs and each dose container communicates with the respective airway passages of the upper and lower discs (block 450). Upper and lower discs are attached to hold the dose vessel discs between them to provide a dose vessel assembly (block 460).
The following exemplary claims are presented herein to support one or more devices, features, and methods of embodiments of the present invention. Although not specifically described below, Applicants may combine or combine with other features illustrated or described in this application, eg, by way of example only, of any of the original claims. It reserves the right to claim one or more of the following features that are subordinate to or replace any of the original claims.
The dose container assembly may include two or more stacked discs. These stacked discs may be located below or above one airway disc, or between a pair of airway discs.
A dry powder doze container assembly with 30 doze container openings in the first row and 30 doze containers in the second row, the airway passage of the first airway disc. Has alternating passages of different radius lengths, one length corresponding to the passage extending from the inner or outer circumference of the airway disc to the dough container in the first row. The dry powder dough container assembly, the other length of which corresponds to the passage extending from the inner or outer circumference of the airway disc to the dough container in the second row.
A dry powder doze vessel assembly in which the first airway disc is attached to the doze vessel disc so that it can rotate together, and the airway passage extends radially across the first airway disc. A dry powder doss container assembly that is positioned relative to the doss container disc so that at least one airway passage is aligned with at least one doss container.
A dry powder dose container assembly, combined with an aspirator, which includes an inhaler body with an inhalation port and a puncture mechanism, which during operation is the airway of the first airway disc. It travels through the disc opening, pierces and enters the first and second sealing layers, and then remains in at least the second disc airway passage while blocking the first airway disc opening, or said the second. A dry powder dose container assembly that is configured to recede from the airway passages.
The inhaler either indexs / punctures / delivers or punctures / delivers / indexes (this index isolates the upper and lower airway passages corresponding to the already opened dose container from the inhalation pathway. ) Is configured.
The doze container disc comprises a first row of doze containers circumferentially separated at a first radius and a second row of doze containers circumferentially separated at a second radius. The first and second columns are concentric with respect to the center of the disk. The piercing mechanism comprises first and second piercing tools, the first piercing tool being configured to pierce the sealant above and below the respective dose vessel openings in the first row. The second piercing tool is configured to pierce the sealant above and below the respective dose vessel openings in the second row.
The puncture mechanism pierces the sealant above and below the dose vessel in the first row of the dose vessel opening by repetitively reciprocating between rows, and then the dose vessel in the second row of the dose vessel opening. It is configured to pierce the top and bottom sealants.
The piercing mechanism comprises a grooved piercing tool configured to pierce the sealant.
The grooved piercing tool comprises three or four lobes, and the first airway disc opening has a corresponding three or four lobe peripheries.
An inhaler with a piercing mechanism equipped with a solid piercing tool.
An inhaler having a circular doze container disc with multiple dry powder chambers isolated in the circumferential direction and a first airway disc located above or below the doze container disc, wherein the airway disc is circumferential. It has multiple radially oriented airway passages that are directionally separated, and one airway passage is arranged in a straight line with one of the dose containers, defining an airway path. The path is such that the airflow exits each dose container and then, along with the dry powder mixed in the airflow, passes through one or more 90 ° repositioning sections, thereby preventing agglomeration. Is an inhaler.
In a dry powder inhaler An inhaler body with an inhalation port and A dose vessel assembly held within the inhaler body, the dose vessel assembly is located under the dose vessel disc with multiple openings separated in the circumferential direction (extending upwards). It comprises a lower airway disc with multiple airway passages (with side walls), each of which communicates with at least one dose vessel opening, thereby causing the lower airway. The disc passages, with the dose vessel assembly, define multiple isolated inhalation delivery routes that individually communicate with the inhalation port. A doze container opening mechanism inside the inhaler body configured to open the doze container at the dosing position in the inhaler, An indexing mechanism inside the inhaler body configured to rotate the dose container assembly to the dosing position, Consists of a dry powder inhaler.
In a dry powder inhaler An inhaler body with an inhalation port and A dose container assembly held inside the inhaler body A dose container disc having opposite upper and lower main surfaces and a plurality of openings separated in the circumferential direction, wherein the first and second sealants are the upper and lower main surfaces of the dose container disc. A doze container disc, which is attached to a surface and defines the floor and ceiling of each doze container opening, thereby forming a sealed doze container that holds dry powder. An upper airway disc that is located above the dose container disc and has multiple airway passages that are circumferentially separated (with a side wall that extends downward). A lower airway disc located beneath the dose container disc, which has multiple airway passages isolated in the circumferential direction (with side walls extending upward). A pair of lower airway disc passages and upper airway disc passages are arranged side by side with at least one corresponding dose container sandwiched between them, with the lower airway discs, With a dose container assembly, A doze container opening mechanism configured to open the doze container at the dosing position in the inhaler, An indexing mechanism configured to rotate the dose vessel assembly to the dosing position, Consists of a dry powder inhaler.
The upper airway disc optionally has circumferentially spaced openings, one of which is located above the corresponding dose container, and the opening mechanism is the first and first. It has a piercing head configured to pierce the sealing layer of 2. The dose vessel openings are optionally arranged in a staggered concentric structure in the inner and outer rows.
The puncture head is configured to occlude or seal each upper airway disc opening during inhalation.
The opening mechanism comprises a member configured to substantially seal the upper airway disc during inhalation.
In the method of operating the inhaler A step of providing a dose vessel ring with staggered concentric dose vessel openings, the dose vessel openings are sealed by being sealed by upper and lower upper and lower sealing layers above and below the openings. A container is defined, a dose vessel ring is attached to at least one of the upper or lower airway discs having multiple airway passages separated in the circumferential direction, and at least one dose vessel is attached to each airway passage. Corresponds to the steps and With the step of rotating the dose vessel ring and at least one airway disc together to bring each dose vessel and corresponding airway passage to the dosing position within the inhaler. Steps to advance the puncture mechanism, open both sealing layers, and release dry powder from the dose vessel into the corresponding airway passages, The step of delivering the dose of the released dry powder to the user by inhalation, With the step of isolating the airway passage associated with the already released dry powder from the inhalation passage so that the passage is reused only once or not used for any subsequent inhalation delivery. A method consisting of.
The method may optionally include retracting the puncture mechanism partially or completely during the delivery step, leaving at least the anterior portion of the puncture mechanism within the airway disc opening associated with the airway disc. it can
The method can include completely retracting the puncture mechanism from the airway disc opening after the delivery step.
The isolation step described above may be performed in response to the fully retracted step by automatically indexing the dose vessel ring when the puncture mechanism is fully retracted.
The isolation step may be performed in response to the opening and closing of the cover by automatically indexing the dose vessel ring upon opening and closing of the cover associated with the inhaler.
This method can include fluidizing the released dry powder to the user by inhalation out of the mouthpiece through the airway passage associated with the released dry powder prior to a complete retreat step. ..
The sealed doze containers may be staggered concentrically in the front and back rows, where the indexing and forward steps continuously open one doze container in the front row and then one in the back row. It will be done as if opening one dose container.
In a dry powder inhaler Circular doze container disc assembly with circumferentially isolated airway passages held in first and second concentric rows of different radii. Aligned with the sealed drug chamber (including dry powder) of the airway, there is no drag in the airway passage before active administration, and one end of the airway passage communicates with the mouthpiece. A circular dose container disc assembly that defines the outlet flow path, A mouthpiece that is rotatably engaged with the outer circumference of the dose container disc, continuously communicates with the airway passage, takes in dry powder from the opened drug chamber, and delivers the dry powder to the user. A puncture mechanism configured to open the dose vessel chamber and release the dry powder in the chamber. An indexing mechanism linked to a circular dose disc, Consists of a dry powder inhaler.
A dry powder inhaler with a circular dough container disc having a plurality of circumferentially isolated dose chambers and a plurality of circumferentially isolated airway passages, the airway. One of the passages is arranged in a straight line with one or more dose chambers, during inhalation, air is inhaled along the radius associated with the airway passage, along with dry powder mixed in the air. A dry powder inhaler that is designed to drain from the vessel.
The above description is merely an example of the present invention and should not be construed as limiting the present invention. Although some exemplary embodiments of the invention have been described, those skilled in the art can make many modifications to the exemplary embodiments without substantially departing from the novel suggestions and advantages of the invention. You will easily understand that there is. Therefore, all such modifications are intended to be included within the scope of the invention described in the claims. Within the scope of claims, means -plus -function clauses), when used, are intended to include not only the structures and structural equivalents described herein as performing the listed functions, but also equivalent structures. There is. Therefore, the above description is merely an example of the present invention and should not be construed as being limited to the particular embodiments disclosed, with modifications to the disclosed embodiments and other embodiments attached. Please understand that it is intended to be included in the claims. The present invention is defined by the following claims, and the equivalent of the claims should be included in the claims.
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| JP2021105213A | Cited by | Japan | Search report |
| WO0134234A1 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| JP2003512102A | Cites | Japan | Examiner |
| JP2004527271A | Cites | Japan | Search report |
| WO2005044173A1 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| US2007235029A1 | Cites | United States of America | Examiner |
| JP2007520247A | Cites | Japan | Examiner |
| JPH09504455A | Cites | Japan | Examiner |
68 members in 12 offices
Priority claims11
| Document | Office | Kind | Date |
|---|---|---|---|
| 10048208 | United States of America | P | |
| 61100482 | United States of America | – | |
| 14852009 | United States of America | P | |
| 61148520 | United States of America | – | |
| 2009058285 | United States of America | W | |
| 2008100482 | – | – | – |
| 2009148520 | – | – | – |
| 2009058285 | – | – | – |
| US20080100482P | – | – | – |
| US20090148520P | – | – | – |
| WO2009US58285 | – | – | – |
Members68
| Document | Office | Kind | |
|---|---|---|---|
| AU2009296535A1 | Australia | A1 | |
| AU2009296538A1 | Australia | A1 | |
| CA2732826A1 | Canada | A1 | |
| CA2732840A1 | Canada | A1 | |
| CA2732842A1 | Canada | A1 | |
| US2010078021A1 | United States of America | A1 | |
| US2010078022A1 | United States of America | A1 | |
| WO2010036355A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2010036836A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2010036839A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2010036355A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2010036839A3 | World Intellectual Property Organization (WIPO) | A3 | |
| MX2011003232A | Mexico | A | |
| MX2011003233A | Mexico | A | |
| MX2011003244A | Mexico | A | |
| KR20110063559A | Republic of Korea | A | |
| KR20110063560A | Republic of Korea | A | |
| US2011162648A1 | United States of America | A1 | |
| EP2346554A2 | European Patent Office (EPO) | A2 | |
| EP2346556A1 | European Patent Office (EPO) | A1 | |
| EP2346557A2 | European Patent Office (EPO) | A2 | |
| CN102159269A | China | A | |
| CN102159270A | China | A | |
| JP2012503530A | Japan | A | |
| JP2012503531AThis record | Japan | A | |
| EP2346554A4 | European Patent Office (EPO) | A4 | |
| US8381721B2 | United States of America | B2 | |
| AU2009296535B2 | Australia | B2 | |
| US2013118490A1 | United States of America | A1 | |
| US2013133653A1 | United States of America | A1 | |
| AU2009296538B2 | Australia | B2 | |
| AU2009296538B8 | Australia | B8 | |
| KR101311977B1 | Republic of Korea | B1 | |
| US8550071B2 | United States of America | B2 | |
| US8671938B2 | United States of America | B2 | |
| JP5470393B2 | Japan | B2 | |
| CN102159269B | China | B | |
| US2014137864A1 | United States of America | A1 | |
| CN102159270B | China | B | |
| JP2014138861A | Japan | A | |
| JP5592381B2 | Japan | B2 | |
| EP2346556B1 | European Patent Office (EPO) | B1 | |
| US8887722B2 | United States of America | B2 | |
| JP2014237011A | Japan | A | |
| ES2528657T3 | Spain | T3 | |
| SI2346556T1 | Slovenia | T1 | |
| US8985103B2 | United States of America | B2 | |
| US2015157812A1 | United States of America | A1 | |
| EP2346554B1 | European Patent Office (EPO) | B1 | |
| ES2550309T3 | Spain | T3 | |
| JP5809301B2 | Japan | B2 | |
| BRPI0919044A2 | Brazil | A2 | |
| BRPI0919126A2 | Brazil | A2 | |
| EP2346557B1 | European Patent Office (EPO) | B1 | |
| JP5903132B2 | Japan | B2 | |
| ES2570128T3 | Spain | T3 | |
| CA2732840C | Canada | C | |
| KR101650075B1 | Republic of Korea | B1 | |
| EP2346557B9 | European Patent Office (EPO) | B9 | |
| US9597465B2 | United States of America | B2 | |
| US2017143916A1 | United States of America | A1 | |
| CA2732826C | Canada | C | |
| US9795749B2 | United States of America | B2 | |
| CA2732842C | Canada | C | |
| US10493222B2 | United States of America | B2 | |
| BRPI0919044B1 | Brazil | B1 | |
| BRPI0919044B8 | Brazil | B8 | |
| BRPI0919126B1 | Brazil | B1 |
26 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Cancellation because of no payment of annual feesLAPS | LAPS | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Receipt of annual feesJAPANESE INTERMEDIATE CODE: R250R250 | R250 | |
| Certificate of patent or registration of utility modelJAPANESE INTERMEDIATE CODE: R150R150 | R150 | |
| First payment of annual fees (during grant procedure)JAPANESE INTERMEDIATE CODE: A61A61 | A61 | |
| Written decision to grant a patent or to grant a registration (utility model)JAPANESE INTERMEDIATE CODE: A01A01 | A01 | |
| Decision of grant or rejection writtenTRDD | TRDD | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Notification of reasons for refusalJAPANESE INTERMEDIATE CODE: A131A131 | A131 | |
| Request for written amendment filedJAPANESE INTERMEDIATE CODE: A523A521 | A521 | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Written permission of extension of timeJAPANESE INTERMEDIATE CODE: A602A602 | A602 | |
| Written request for extension of timeJAPANESE INTERMEDIATE CODE: A601A601 | A601 | |
| Notification of reasons for refusalJAPANESE INTERMEDIATE CODE: A131A131 | A131 | |
| Report on accelerated examinationJAPANESE INTERMEDIATE CODE: A971005A975 | A975 | |
| Request for written amendment filedJAPANESE INTERMEDIATE CODE: A523A521 | A521 | |
| Explanation of circumstances concerning accelerated examinationJAPANESE INTERMEDIATE CODE: A871A871 | A871 | |
| Request for written amendment filedJAPANESE INTERMEDIATE CODE: A523A521 | A521 | |
| Written request for application examinationJAPANESE INTERMEDIATE CODE: A621A621 | A621 |
Numbers
- Publication
- 2012503531
- Publication, DOCDB
- 2012503531
- Publication, EPODOC
- JP2012503531
- Application
- 2011529238
- Application, DOCDB
- 2011529238
- Application, EPODOC
- JP20110529238
Titles2
- Japanese
- 個別気道通路を有する吸入器ならびに関連するディスクおよび方法
- English
- Inhalers with individual airway passages and associated discs and methods
Classification
- CPC, 10
- A61M15/0048
- A61M15/00
- A61M15/0045
- A61M15/0075
- Y10T29/49826
- A61J1/05
- A61M2202/064
- A61M15/0021
- A61M15/0035
- A61M15/0041
- IPC, 4
- A61M15 00
- A61J1 03
- A61J7 00
- B65D83 06
Designated states4
- Regional, 4
- Zimbabwe
- Turkmenistan
- Türkiye
- Togo